UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period
ended
OR
From the transition period from to
Commission File Number:
(Exact name of registrant as specified in the charter)
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone
number, including area code:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. ☒
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check
mark if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒
There were
VIRPAX PHARMACEUTICALS, INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE FISCAL PERIOD ENDED SEPTEMBER 30, 2021
INDEX
i
Part I
Item 1: Financial Statements
VIRPAX Pharmaceuticals, Inc.
CONDENSED BALANCE SHEETS
| September 30, 2021 | December 31, 2020* | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | $ | ||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Deferred financing costs | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
| Accounts payable and accrued expenses | $ | $ | ||||||
| Notes payable | ||||||||
| Total current liabilities | ||||||||
| Notes payable, net of current portion | ||||||||
| Related party notes payable | ||||||||
| Total long-term liabilities | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity (deficit) | ||||||||
| Preferred stock, par value $ | ||||||||
| Common stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity (deficit) | ( | ) | ||||||
| Total liabilities and stockholders’ equity (deficit) | $ | $ | ||||||
| * |
See Notes to the Condensed Financial Statements
1
VIRPAX Pharmaceuticals, Inc.
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
For
the Three | For
the Three | For the Nine Months Ended September 30, 2021 | For the Nine | |||||||||||||
| OPERATING EXPENSES | ||||||||||||||||
| General and administrative | $ | $ | $ | $ | ||||||||||||
| Research and development | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| OTHER (EXPENSE) INCOME | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense), net | ||||||||||||||||
| Loss before tax provision | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Benefit from income taxes | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Basic and diluted net loss per share | ( | ) | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Basic and diluted weighted average common stock outstanding | ||||||||||||||||
See Notes to the Condensed Financial Statements
2
VIRPAX Pharmaceuticals, Inc.
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
(UNAUDITED)
| Additional | Total | |||||||||||||||||||||||||||
| Preferred stock | Common stock | paid-in | Accumulated | stockholders’ | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | capital | deficit | equity/(deficit) | ||||||||||||||||||||||
| Balance at December 31, 2019 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
| Common stock issued pursuant to subscription agreements | — | |||||||||||||||||||||||||||
| Common stock issued in payment of consulting services and settlement of accounts payable | — | |||||||||||||||||||||||||||
| Stock-based compensation | — | — | ||||||||||||||||||||||||||
| Restricted stock awards granted | — | |||||||||||||||||||||||||||
| Net loss | — | — | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at March 31, 2020 | ( | ) | ( | ) | ||||||||||||||||||||||||
| Common stock issued pursuant to subscription agreements | — | — | ||||||||||||||||||||||||||
| Common stock issued in payment of consulting services and settlement of accounts payable | — | — | ||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | |||||||||||||||||||||||||
| Restricted stock awards granted | — | — | ||||||||||||||||||||||||||
| Restricted stock awards forfeited | — | — | ( | ) | ||||||||||||||||||||||||
| Net loss | — | — | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at June 30, 2020 | ( | ) | ( | ) | ||||||||||||||||||||||||
| Common stock issued pursuant to subscription agreements | — | |||||||||||||||||||||||||||
| Common stock issued in payment of consulting services and settlement of accounts payable | — | |||||||||||||||||||||||||||
| Stock-based compensation | — | — | ||||||||||||||||||||||||||
| Net loss | — | — | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at September 30, 2020 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
| Balance at December 31, 2020 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
| Common stock issued pursuant to initial public offering, net of offering costs of $ | — | |||||||||||||||||||||||||||
| Stock-based compensation | — | — | ||||||||||||||||||||||||||
| Net loss | — | — | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at March 31, 2021 | ( | ) | ||||||||||||||||||||||||||
| Restricted stock awards granted | — | ( | ) | |||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | ||||||||||||||||||||||||
| Net loss | — | — | — | — | — | ( | ) | ( | ) | |||||||||||||||||||
| Balance at June 30, 2021 | ( | ) | ||||||||||||||||||||||||||
| Common stock issued pursuant to secondary offering, net of expenses | — | |||||||||||||||||||||||||||
| Cashless exercise of stock options and warrants | — | |||||||||||||||||||||||||||
| Stock-based compensation | — | — | ||||||||||||||||||||||||||
| Restricted stock awards forfeited | — | ( | ) | |||||||||||||||||||||||||
| Net loss | — | — | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at September 30, 2021 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||
See Notes to the Condensed Financial Statements
3
VIRPAX Pharmaceuticals, Inc.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
For
the Nine | For the Nine Months Ended September 30, 2020 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Non-cash interest expense | ||||||||
| Forgiveness of PPP loan | ( | ) | ||||||
| Stock-based compensation | ||||||||
| Common stock issued in payment of consulting services and settlement of accounts payable | ||||||||
| Change in operating assets and liabilities: | ||||||||
| Prepaid expenses and other current assets | ( | ) | ( | ) | ||||
| Accounts payable and accrued expenses | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Repayment of notes payable | ( | ) | ||||||
| Proceeds from the issuance of debt | ||||||||
| Proceeds from related party notes payable | ||||||||
| Repayment of related party notes payable | ( | ) | ||||||
| Proceeds from the issuance of stock | ||||||||
| Offering costs related to secondary offering | ( | ) | ||||||
| Proceeds from secondary offering of common stock | ||||||||
| Offering costs related to initial public offering | ( | ) | ||||||
| Proceeds from initial public offering of common stock | ||||||||
| Net cash provided by financing activities | ||||||||
| Net change in cash | ||||||||
| Cash, beginning of period | ||||||||
| Cash, end of period | $ | $ | ||||||
| Supplemental disclosure of cash and non-cash financing activities | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Cash paid for taxes | $ | $ | ||||||
| Common stock issued in payment of consulting services and settlements of accounts payable | $ | $ | ||||||
| Deferred financing costs, included in accounts payable and accrued expenses | $ | $ | ||||||
| Debt issued in payment of consulting services and settlement of accounts payable | $ | $ | ||||||
See Notes to the Condensed Financial Statements
4
VIRPAX Pharmaceuticals, Inc.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Business and Liquidity
Business
Virpax Pharmaceuticals, Inc. (“Virpax” or the “Company”) was incorporated on May 12, 2017 in the state of Delaware. Virpax is a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems. Virpax has exclusive global rights to a proprietary patented Topical Spray Film Delivery Technology for osteoarthritis pain (“Epoladerm”). Virpax also has exclusive global rights to a proprietary patented injectable “local anesthetic” Liposomal Gel Technology for postoperative pain management (“Probudur”). Additionally, Virpax has exclusive global rights to a proprietary patented Nanomerics’ Molecular Envelope Technology (“MET”) that uses an intranasal device to deliver enkephalin for the management of acute and chronic pain, including pain associated with cancer (“NES100”). NES100 would support the current effort among prescribers, regulators, and patients to seek non-opioid and non-addictive treatment options to combat the opioid epidemic. Virpax will utilize these delivery technologies to selectively develop a portfolio of patented 505(b)(2) and new chemical entity (“NCE”) candidates for commercialization. While the Company is currently focused on the development of its non-opioid and non-addictive pain management pipeline of product candidates, the Company also plans on using its proprietary delivery technologies to develop anti-viral therapies (“AnQlar”) as an anti-viral barrier to potentially prevent or reduce the risk or the intensity of viral infections in humans, including, but not limited to, influenza and SARS-CoV-2 (COVID 19).
The Company, since inception, has been engaged in organizational activities, including raising capital and research and development activities. The Company has not generated revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flow from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any preclinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.
The Company incurred a net loss of $
On February 16, 2021, the Company announced the
pricing of its initial public offering (the “IPO”) of
On September 16, 2021, the Company announced the
closing of an underwritten public offering of
In addition, with respect to the ongoing and evolving coronavirus (“COVID-19”) outbreak, which was designated as a pandemic by the World Health Organization on March 11, 2020, the outbreak has caused substantial disruption in international and U.S. economies and markets and if repercussions of the outbreak are prolonged, could have a significant adverse impact on the Company’s business.
Management believes that current cash, including the proceeds from our initial public offering and the underwritten offering in September 2021, is sufficient to fund operations and capital requirements into 2024. Additional financings will be needed by the Company to fund its operations, to complete clinical development of and to commercially develop all of its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms. The Company also has the ability to curtail spending in research and development activities in order to conserve cash.
5
Note 2. Summary of Significant Accounting Policies
Basis of Presentation — The interim condensed financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation of the financial position of Virpax at September 30, 2021, and its results of operations and its cash flows for the three and nine months ended September 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the years ended December 31, 2020 and 2019 and notes thereto. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations of the Securities and Exchange Commission (“SEC”) relating to interim financial statements. The December 31, 2020 balance sheet information was derived from the audited financial statements as of that date.
Use of Estimates — The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.
Significant items subject to such estimates and assumptions include research and development accruals and the valuation of stock-based compensation. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.
Basic and Diluted Loss per Share — Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an antidilutive effect. Equivalent common shares excluded from the calculation of diluted net loss per share since their effect is antidilutive due to the net loss of the Company consisted of the following:
Three Months Ended September 30, 2021 | Three Months Ended September 30, 2020 | Nine Months Ended September 30, 2021 | Nine Months Ended September 30, 2020 | |||||||||||||
| Equivalent common shares | ||||||||||||||||
| Stock options | ||||||||||||||||
| Warrants | ||||||||||||||||
| RRD note conversion | ||||||||||||||||
Cash — At times, the
Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. Total cash was $
Fair Value of Financial Instruments — The carrying amounts of the Company’s financial instruments, including cash and accounts payable approximate fair value due to the short-term nature of those instruments.
6
Research and Development — Research and development costs are expensed as incurred. These expenses include the costs of proprietary efforts, as well as costs incurred in connection with certain licensing arrangements and external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available.
Stock-based Compensation — Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. The Company’s policy permits the valuation of stock-based awards granted to non-employees to be measured at fair value at the grant date rather than on an accelerated attribution basis over the vesting period.
Determining the appropriate fair value of share-based awards requires the use of subjective assumptions, including the fair value of the Company’s common shares, and for options, the expected life of the option and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represents management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.
The expected life of options was estimated using the simplified method, as the Company has historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.
Income Taxes — The Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods.
The Company follows the guidance in ASC Topic
740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in
the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether
the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement
of the amount to be recognized. Tax positions that meet the more-likely than-not threshold are measured at the largest amount of tax benefit
that is greater than
Note 3. Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consists of the following:
| September 30, 2021 | December 31, 2020 | |||||||
| Prepaid insurance | $ | $ | ||||||
| Prepaid research and development | ||||||||
| Legal retainer | ||||||||
| Consulting fees | ||||||||
| Other prepaid expenses and current assets | ||||||||
| $ | $ | |||||||
7
Note 4. Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consists of the following:
| September 30, 2021 | December 31, 2020 | |||||||
| Accrued payroll and deferred CEO compensation | $ | $ | ||||||
| Research and development expenses | ||||||||
| Insurance premiums | ||||||||
| Legal expenses | ||||||||
| Professional fees | ||||||||
| Interest payable/accrued | ||||||||
| Accounting consulting fees | ||||||||
| Tax expenses | ||||||||
| Other | ||||||||
| $ | $ | |||||||
Note 5. Notes Payable
On October 1, 2018, the Company entered into a
promissory note (the “2018 Promissory Note”), which promised to pay Anthony Mack, Chief Executive Officer and significant
investor, the principal amount of $
On January 15, 2019, the Company entered into
a promissory note (the “2019 Promissory Note”), which promised to pay Anthony Mack the principal amount of $
In January 2021,
8
On August 29, 2019, the Company entered into a
service provider convertible note purchase agreement (the “RRD Note”) with RRD International, LLC (“RRD”). Under
the RRD Note, the Company and RRD agreed to make certain compensation due to RRD payable in the form of a convertible promissory note.
The RRD Note stated that a maximum principal balance of $
In February 2021, the Company fully paid the balance
on its RRD Note of $
On May 4, 2020, the Company entered into a Promissory
Note (the “PPP Note”) with PNC Bank as the lender (the “Lender”), pursuant to which the Lender agreed to make
a loan to the Company under the Paycheck Protection Program (the “PPP Loan”) offered by the U.S. Small Business Administration
(the “SBA”) in a principal amount of $
The following table summarizes the Company’s notes payables:
| September 30, 2021 | ||||||||||||||||||||
| Balance as of January 1, 2021 | Debt Forgiveness | Notes Issued | Note Payments | Balance as of September 30, 2021 | ||||||||||||||||
| Related party notes payable | ||||||||||||||||||||
| Anthony Mack 2018 Promissory Note | $ | $ | $ | $ | ( | ) | $ | |||||||||||||
| Anthony Mack 2019 Promissory Note | ( | ) | ||||||||||||||||||
| Related party notes payable | ( | ) | ||||||||||||||||||
| Total related party notes payable | ( | ) | ||||||||||||||||||
| RRD Note | ( | ) | ||||||||||||||||||
| SBA PPP Loan | ( | ) | ( | ) | ||||||||||||||||
| Total notes payable | ( | ) | ( | ) | ||||||||||||||||
| Less: Current portion of notes payable | ( | ) | ( | ) | ||||||||||||||||
| Total non-current portion of notes payable | $ | $ | $ | $ | ( | ) | $ | |||||||||||||
Interest expense was $
9
Note 6. Commitments and Contingencies
Employment Agreements
The Company has an employment agreement with Anthony
Mack, the Company’s Chief Executive Officer (“CEO”), effective September 18, 2018. The agreement may be terminated by
either party at any time upon written notice provided to the other party. Concurrent with the employment agreement, the CEO and the Company
agreed to an Executive Confidentiality Agreement that contains standard non-closure and non-competition provisions. In the event we terminate
the employment agreement other than for cause, or the CEO terminates the agreement for good reason, we will pay the CEO the then effective
base salary for a period of twelve months following the effective date of the termination. However, payment of the effective base salary
is subject to the execution of a release form and the compliance by the CEO with the release and all terms and provisions of the employment
agreement and Executive Confidentiality Agreement that survive the termination of employment. The Company’s Chief Executive Officer
also elected to defer salary temporarily. Deferred compensation due to the Company’s Chief Executive Officer amounted to $
Litigation
From time to time the Company is subject to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.
On March 12, 2021, the Company and Mr. Mack (the “Defendants”) were named as defendants in a complaint (the “Complaint”) filed by Sorrento Therapeutics, Inc. (“Sorrento”), and Scilex Pharmaceuticals Inc. (“Scilex” and together with Sorrento, the “Plaintiffs”) in the Court of Chancery of the State of Delaware. In the Complaint, the Plaintiffs alleged (i) Mr. Mack breached a Restrictive Covenants Agreement, dated as of November 8, 2016, between himself and Sorrento (the “Restrictive Covenants Agreement”), (ii) the Company tortiously interfered with the Restrictive Covenants Agreement, and (iii) the Company tortiously interfered with Scilex’s relationship with Mr. Mack. On May 7, 2021 Plaintiffs filed an Amended Complaint (the “First Amended Complaint”) asserting the same three causes of action. Simultaneously with filing the original Complaint, Plaintiffs filed a motion to expedite, seeking a hearing on their prospective motion for a preliminary injunction, prohibiting Mr. Mack’s alleged violations of the Restrictive Covenants Agreement and prohibiting the alleged tortious interference. On March 22, 2021, Vice Chancellor Paul A. Fioravanti Jr. issued a scheduling order, setting forth terms which had been agreed to by the parties, under which oral argument on Plaintiffs’ proposed motion for preliminary injunction was scheduled for July 15, 2021. On May 18, 2021, the Vice Chancellor issued a revised scheduling order, also setting forth terms which had been agreed to by the parties, under which Plaintiffs agreed not to move for a preliminary injunction and a trial in the action was set for February 9-11, 2022. On September 28, 2021, Plaintiffs filed a Second Amended Verified Complaint asserting the same three causes of action as the prior complaints, as well as additional claims in which Plaintiffs allege (i) Mr. Mack breached an Employment, Proprietary Information and Inventions Agreement, dated as of October 25, 2016, between himself and Sorrento (the “Employment Agreement”), (ii) the Company tortiously interfered with the Employment Agreement, (iii) Mr. Mack breached his fiduciary duties to Scilex, and (iv) the Company aided and abetted Mr. Mack’s alleged breach of fiduciary duties to Scilex. On October 18, 2021, Defendants filed an Answer to the Second Amended Complaint, and subsequently withdrew a previously filed motion to dismiss the first Amended Complaint. We intend to vigorously defend the action. However, we are unable to predict the ultimate outcome of the lawsuit at this time.
10
Global Pandemic Outbreak
In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (“COVID-19”) a global pandemic. The outbreak has become increasingly widespread in the United States, impacting the markets in which the Company operates. While the full impact of the pandemic continues to evolve, the financial markets have been subject to significant volatility that adversely impacts the Company’s ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset values also affect the Company’s ability to enter into collaborations, joint ventures, and license and royalty agreements. The outbreak and government measures taken in response to the pandemic have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, have spiked, while demand for other goods and services, such as travel, have fallen. The future progression of the outbreak and its effects on our business and operations are uncertain. We may face difficulties recruiting or retaining patients in our ongoing and planned clinical trials if patients are affected by the virus or are fearful of traveling to our clinical trial sites because of the outbreak. We and our third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to our research and development activities, including, for example, medical and laboratory supplies used in our clinical trials or preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak.
While expected to be temporary, these disruptions may negatively impact the Company’s results of operations, financial condition, and liquidity in 2021 and potentially beyond.
Note 7. Stockholders’ Equity
Overview
Preferred Stock
The Company’s Certificate of Incorporation,
filed on May 12, 2017, and amended and restated on February 16, 2021, authorizes the issuance of preferred stock. The total number of
shares which the Company is authorized to issue is
Common Stock
The Company’s Certificate of Incorporation,
filed on May 12, 2017, and amended and restated on February 16, 2021, authorizes the issuance of common stock. The total number of shares
which the Company is authorized to issue is
On February 19, 2021, the Company issued
During the three and nine months ended September 30,
2020, the Company issued
In addition, during the three and nine months
ended September 30, 2020, the Company issued
Warrants
In conjunction with the IPO, the Company granted
the underwriters warrants to purchase
The Company issued
11
Reverse Stock Split
On November 19, 2020,
Note 8. Stock-Based Compensation
Restricted Stock Awards
On May 20, 2017, the Company established the Virpax Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (the “Plan”). The Company’s Board of Directors (the “Board”), acting through its Equity Incentive Plan Committee, has determined that it would be to the advantage and best interest of the Company and its stockholders to grant restricted stock awards to certain individuals as compensation to serve as an employee of the Company and as an incentive for increased efforts during such service.
There were 10,420 and 5,506 unvested restricted stock awards issued totaling $61,875 and $50,000 based on a fair value of the Company’s common stock on the date of grant, as of September 30, 2021 and December 31, 2020, respectively. During the three months ended September 30, 2021 and 2020, there were no restricted stock awards granted and 640 and 0 of restricted stock awards were forfeited, respectively. The Company recognized $22,013 and $0 of stock based compensation for vested restricted shares during the three months ended September 30, 2021 and 2020, respectively.
During the nine months ended September 30, 2021 and 2020, there were 15,000 and 6,952 restricted stock awards granted, respectively, and 640 and 20,225 of restricted stock awards were forfeited, respectively. The Company recognized $57,425 and $156,250 of stock based compensation for vested restricted shares during the nine months ended September 30, 2021 and 2020, respectively.
Stock Options
The Plan provides a means for eligible employees,
officers, non-employee directors and other individual service providers (collectively, “eligible persons”) to develop a sense
of proprietorship and personal involvement in the development and financial success of the Company and to encourage them to devote their
best efforts to the business of the Company, thereby advancing the interests of the Company and its stockholders. The Company, by means
of the Plan, seeks to retain the services of such eligible persons and to provide incentives for such eligible persons to exert maximum
efforts for the success of the Company. The Plan commenced on May 20, 2017 (the “Effective Date”) and is administered by the
Compensation Committee of the Board (the “Compensation Committee”); provided that the entire Board may act in lieu of the
Compensation Committee on any matter. The maximum aggregate number of shares of common stock which may be issued under all awards granted
to participants under the Plan initially shall be
On April 25, 2020, the Company amended and restated
the Plan to grant stock options to non-employee directors. Stock options to purchase
12
Stock-based compensation expense for the three
months ended September 30, 2021 and 2020 was $
Stock-based compensation expense for the nine
months ended September 30, 2021 and 2020 was $
The fair value of option awards is estimated using the Black-Scholes option-pricing model. Exercise price of each award is generally not less than the per share fair value in effect as of that award date. The determination of fair value using the Black-Scholes model is affected by the Company’s share fair value as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest rate and projected employee share option exercise behaviors. Options granted or modified under the Plan during the nine months ended September 30, 2021 and 2020 were valued using the Black-Scholes option-pricing model with the following weighted-average assumptions:
| For the Nine Months Ended September 30, |
||||||||
| 2021 | 2020 | |||||||
| Expected term (years) | ||||||||
| Risk-free interest rate | % | % | ||||||
| Expected volatility | % | % | ||||||
| Expected dividend yield | % | % | ||||||
The Company estimates its expected volatility by using a combination of historical share price volatilities of similar companies within our industry. The risk-free interest rate assumption is based on observed interest rates for the appropriate term of the Company’s options on a grant date. The expected option term assumption is estimated using the simplified method and is based on the mid-point between vest date and the remaining contractual term of the option, since the Company does not have sufficient exercise history to estimate expected term of its historical option awards.
13
The following is a summary of stock option activity under the stock option plan for the nine months ended September 30, 2021 and for the year ended December 31, 2020:
| Number of Shares | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Term (Years) | Aggregate Intrinsic Value | |||||||||||||
| Options outstanding at January 1, 2020 | $ | $ | ||||||||||||||
| Forfeited | ( | ) | ||||||||||||||
| Granted | ||||||||||||||||
| Options outstanding at December 31, 2020 | ||||||||||||||||
| Forfeited | ||||||||||||||||
| Exercised | ( | ) | ||||||||||||||
| Granted | - | |||||||||||||||
| Options outstanding at September 30, 2021 | $ | $ | ||||||||||||||
| Options exercisable at September 30, 2021 | $ | $ | ||||||||||||||
The weighted-average grant-date fair value of
stock options granted during the nine months ended September 30, 2021 and year ended December 31, 2020 was $
As of September 30, 2021, there was $
Note 9. Related-Party Transactions
As discussed in Note 6, the Company’s Chief
Executive Officer elected to temporarily defer his salary. Deferred compensation due to the Company’s Chief Executive Officer amounted
to $
Note 10. Research and Development and License Agreements
MedPharm Limited
Research and Option Agreement
On April 11, 2017, the Company entered into a research and option agreement, as amended on May 30, 2018 (the “MedPharm Research and Option Agreement”), with MedPharm Limited, a company organized and existing under the laws of the United Kingdom (“MedPharm”), pursuant to which MedPharm granted the Company an option to obtain an exclusive, world-wide, royalty bearing license to use certain technology developed by MedPharm. Pursuant to the agreement, MedPharm will conduct certain research and development of proprietary formulations incorporating certain MedPharm technologies and certain of the Company’s proprietary molecules.
Under the MedPharm Research and Option Agreement, MedPharm granted the Company an option (the “MedPharm Option”) to obtain an exclusive (even to MedPharm), worldwide, sub-licensable (through multiple tiers), royalty bearing, irrevocable license to research, develop, market, commercialize, and sell any product utilizing MedPharm’s spray formulation technology which is the result of the activities performed under the MedPharm Research and Option Agreement, subject to the Company’s entry into a definitive license agreement with MedPharm. In order to exercise the MedPharm Option, the Company must provide MedPharm with written notice of such exercise before the end of the Option Period (as defined in the MedPharm Research and Option Agreement). The Option Period is subject to extension upon mutual agreement with MedPharm.
14
Pursuant to the MedPharm Research and Option Agreement, the Company has a right of first refusal with respect to any license or commercial arrangement involving any Licensed Intellectual Property (as defined in the MedPharm Research and Option Agreement) in combination with any Virpax Molecule (as defined in the MedPharm Research and Option Agreement). In the event that MedPharm reaches an agreement with respect to a license or other commercial arrangement that involves technology or molecules covered by the right of first refusal, the Company has ten business days from the date of notice to notify MedPharm of its intention to exercise the right of first refusal and the Company’s intention to match the financial terms of the other license or commercial arrangement.
License Agreement
On June 6, 2017, as a result of the Company’s
exercise of the MedPharm Option under the MedPharm Research and Option Agreement, the Company entered into a license agreement, as amended
on September 2, 2017 and October 31, 2017 (the “MedPharm License Agreement”), with MedPharm for the exclusive global rights
to discover, develop, make, sell, market, and otherwise commercialize any pharmaceutical composition or preparation (in any and all dosage
forms) in final form containing one or more compounds, including Diclofenac Epolamine (“Epoladerm”), that was developed, manufactured
or commercialized utilizing MedPharm’s spray formulation technology (“MedPharm Product”), to be used for any and all
uses in humans (including all diagnostic, therapeutic and preventative uses). Under the MedPharm License Agreement, the Company is required
to make future milestone and royalty payments to MedPharm. We are obligated to make aggregate milestone payments to MedPharm of up to
GBP
LipoCureRx, Ltd.
On March 19, 2018, the Company entered into a
license and sublicense agreement (the “LipoCure Agreement”) with LipoCureRx, Ltd., a company organized and existing under
the laws of Israel (“LipoCure”), for the sole and exclusive global license and sub-license rights to discover, develop, make,
sell, market, and otherwise commercialize bupivacaine liposome, in injectable gel or suspension (“Licensed Compound”) or any
pharmaceutical composition or preparation (in any and all dosage forms) in final form, including any combination product, containing a
Licensed Compound (“Licensed Product”), including Probudur. Under
Nanomerics Ltd.
Nanomerics Collaboration Agreement
On April 11, 2019,
15
Under the Nanomerics Collaboration Agreement,
the Company is required to make royalty payments equal to a single digit percentage of annual net sales of royalty qualifying products.
The Company is also required to make aggregate milestone payments of up to $
Nanomerics License Agreement (AnQlar)
On August 7, 2020, the Company entered into a
collaboration and license agreement with Nanomerics (the “Nanomerics License Agreement”) for the exclusive North American
license to develop and commercialize a High-Density Molecular Masking Spray (“AnQlar”) as an anti-viral barrier to prevent
or reduce the risk or the intensity of viral infections in humans. Under the Nanomerics License Agreement, the Company is required to
make royalty payments within a range of
Nanomerics License Agreement (VRP324)
On September 17, 2021, the Company entered into
a collaboration and license agreement with Nanomerics (the “Nanomerics License Agreement - VRP324”) for the exclusive worldwide
license to develop and commercialize an investigational formulation delivered via the nasal route to enhance pharmaceutical-grade cannabidiol
(“CBD”) transport to the brain to potentially treat seizures associated with tuberous
sclerosis complex (TSC), Lennox-Gastaut syndrome and Dravet syndrome in patients one year of age and older. Lennox-Gastaut syndrome and
Dravet syndrome are rare central nervous system diseases considered serious epileptic encephalopathies that cause different types of epileptic
seizures as well as cognitive and behavioral changes and are generally resistant to treatment. Under the Nanomerics License Agreement
– VRP324, the Company is required to make royalty payments within a range of
Research Agreements
Yissum
On May 12, 2019, the Company entered into an Agreement
for Rendering of Research Services (the “May 2019 Yissum Research Agreement”), with Yissum Research Development Company of
the Hebrew University of Jerusalem, Ltd. (“Yissum”). Under the May 2019 Yissum Research Agreement, the Company shall provide
funding for research and development studies to be performed by researchers at Hebrew University related to the formulation, preparation
and characterization of Liposomal Bupivacaine for size zeta potential, drug loading and rate of drug release. In consideration for the
research services, the Company agreed to pay research service fees of $
16
On October 11, 2020,
On June 30, 2021, the Company entered into an
Agreement for Rendering of Research Services with Yissum (the “June 2021 Yissum Research Agreement”) on substantially similar
terms and conditions as detailed above under the October 2020 Yissum Research Agreement. Under the June 2021 Yissum Research Agreement,
the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to
the optimization of the Liposomal Bupivacaine formulation and to increase stability for manufacturing purposes. The Company may terminate
the agreement at any time and shall be only responsible to pay Yissum for work performed through the date of termination. In consideration
for the research services, the Company agreed to pay research service fees of $
Lipocure
On June 29, 2021, the Company entered into an
Agreement for Rendering of Research Services (the “June 2021 Lipocure Research Agreement”) with Lipocure RX, Ltd. (“Lipocure”).
Under the June 2021 Lipocure Research Agreement, the Company shall provide funding for research and development related to the optimization
of the Liposomal Bupivacaine formulation and eventual manufacture of pre-clinical batches including batches for stability testing, animal
studies and toxicology work. This will also include work associated with the potential filing of additional provisional patent applications.
The Company may terminate the agreement at any time upon 30 days written notice and shall be only responsible to pay Lipocure for work
performed through the date of such notice. In consideration for the research services, the Company agreed to pay research service fees
of $
NCATS-NIH Cooperative Research and Development Agreement
On August 25, 2020, the Company entered into a
Cooperative Research and Development Agreement (“CRADA”) with the National Center for Advancing Translational Science (“NCATS”).
This collaboration is for the continued development of the Company’s product candidate, NES100, an intranasal peptide, for the management
of acute and chronic non-cancer pain.
With respect to NCATS rights to any invention made solely by an NCATS employee(s) or made jointly by an NCATS employee(s) and our employee(s), the CRADA grants to the Company an exclusive option to elect an exclusive or nonexclusive commercialization license. For inventions owned solely by NCATS or jointly by NCATS and the Company, and licensed pursuant to the Company’s option, the Company must grant to NCATS a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention practiced throughout the world by or on behalf of the United States government. For inventions made solely by an employee of the Company, we grant to the United States government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention practiced throughout the world by or on behalf of the United States government for research or other government purposes.
Note 11. Subsequent Events
The Company has evaluated subsequent events from the balance sheet date through November 15, 2021. The following are material subsequent events:
17
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, particularly those under “Risk Factors.”
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future.
There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:
| ● | our lack of operating history; |
| ● | the expectation that we will incur significant operating losses for the foreseeable future and will need significant additional capital; |
| ● | our current and future capital requirements to support our development and commercialization efforts for our product candidates and our ability to satisfy our capital needs; |
| ● | our dependence on our product candidates, which are still in preclinical or early stages of clinical development; |
| ● | our, or that of our third-party manufacturers, ability to manufacture current good manufacturing practice (cGMP) quantities of our product candidates as required for pre-clinical and clinical trials and, subsequently, our ability to manufacture commercial quantities of our product candidates; |
| ● | our ability to complete required clinical trials for our product candidates and obtain approval from the FDA or other regulatory agencies in different jurisdictions; |
| ● | our lack of a sales and marketing organization and our ability to commercialize our product candidates if we obtain regulatory approval; |
| ● | our dependence on third-parties to manufacture our product candidates; |
| ● | our reliance on third-party CROs to conduct our clinical trials; |
| ● | our ability to maintain or protect the validity of our intellectual property; |
| ● | our ability to internally develop new inventions and intellectual property; |
18
| ● | interpretations of current laws and the passages of future laws; |
| ● | acceptance of our business model by investors; |
| ● | the accuracy of our estimates regarding expenses and capital requirements; |
| ● | our ability to adequately support organizational and business growth; and |
| ● | the continued spread of COVID-19 and the resulting global pandemic and its impact on our preclinical studies and clinical studies. |
The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipate in our forward-looking statements. Please see “Risk Factors” for additional risks which could adversely impact our business and financial performance.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.
Overview
Company Overview
We are a preclinical-stage pharmaceutical company focused on developing novel and proprietary drug delivery systems across various pain indications in order to enhance compliance and optimize the ability of each product candidate in our pipeline. Our drug-delivery systems, and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for CNS disorders to enhance patients’ quality of life.
We have exclusive global rights to develop, sell and export (among other rights) a proprietary patented nonsteroidal anti-inflammatory Topical Spray Film Delivery Technology for chronic osteoarthritis of the knee (“EpoladermTM”). We also have exclusive global rights to a proprietary patented injectable, long-acting, local anesthetic Liposomal Gel Technology for postoperative pain management (“LBL100” or “ProbudurTM”). Additionally, we have exclusive global rights to a proprietary patented Molecular Envelope Technology (“MET”) that uses an intranasal device to deliver exogenous enkephalin for the management of acute and chronic pain, including pain associated with cancer (“EnveltaTM”) and for the management of Post-Traumatic Stress Disorder (“PES200”). Enkephalins are pain-relieving pentapeptides produced in the body, and function to inhibit neurotransmitters in the pathway for pain perception, thereby reducing the physical impact of pain. While the Company is currently focused on the development of its non-opioid and non-addictive pain management pipeline of product candidates, the Company also plans on using its proprietary delivery technologies to develop anti-viral therapies (“AnQlarTM”) as an anti-viral barrier to potentially prevent or reduce the risk or the intensity of viral infections in humans, including, but not limited to, influenza and SARS-CoV-2 (COVID 19).
Epoladerm
We believe the Topical Spray Film Delivery Technology, which we refer to as Epoladerm, could provide a pathway for additional proprietary spray formulations with strong adhesion and accessibility properties upon application, especially around joints and curved body surfaces. Our belief is based on, in part, an American College of Physicians and American Academy of Family Practice national guideline for the treatment of non-Low Back Musculoskeletal Pain which recommends topical nonsteroidal anti-inflammatory drugs (“NSAIDs”) as the first-line therapy in patients with acute pain from non-low back, musculoskeletal injuries. According to the new guideline, evidence shows that topical NSAIDs were among the most effective for pain reduction, physical function, treatment satisfaction, and symptom relief and were not associated with any significant side effects. The guideline was based on a systematic evidence review of the comparative efficacy and safety of non-pharmacological and pharmacological management of acute pain from non-low back, musculoskeletal injuries in adults in the outpatient setting and a systematic review of the predictors of prolonged opioid use.
Based on results from our recent non-clinical studies and further research of Epoladerm, we have determined that it is reasonable to focus our Epoladerm indication on chronic osteoarthritis of the knee, representing what we believe to be a better global market opportunity for us. Additionally, our ongoing IND enabling studies for Epoladerm will go uninterrupted pursuing the osteoarthritis indication.
19
Pursuant to a research and option agreement, as amended on May 30, 2018 (the “MedPharm Research and Option Agreement”), with MedPharm Limited (“MedPharm”), MedPharm will conduct certain research and development activities of proprietary formulations incorporating certain MedPharm technologies and certain of our proprietary molecules. These proprietary molecules relate to indications which include, but are not limited to, treatment of estrogen levels, Alzheimer’s disease, dementia, Parkinson’s disease, neuropathic issues, and acute and chronic pain. Under the MedPharm Research and Option Agreement, we were granted an option to obtain an exclusive, world-wide, sub-licensable, royalty bearing, irrevocable license to research, develop, make, market, commercialize, and sell any product utilizing MedPharm’s spray formulation technology.
We have initiated a series of IND enabling toxicity studies for Epoladerm which are expected to be completed by mid-2022. Upon successful completion of these studies, we intend to submit an IND application to the FDA, including a trial design for a Phase I study for chronic osteoarthritis of the knee.
Probudur
Probudur is our injectable bupivacaine liposomal hydrogel for postoperative pain management, which we believe to have improved onset and extended duration of action compared to existing treatment options. Charles River Laboratories was engaged to perform seven preclinical animal studies during the second half of 2021, including method, dosage, and toxicity as part of the required FDA enabling trials for an IND for Probudur. However, we elected to strategically delay these trials in order to enhance the formulation of Probudur to increase stability for manufacturing purposes and to possibly extend the lifetime of a relevant patent.
On June 30, 2021, the Company entered into an Agreement for Rendering of Research Services with Yissum (the “June 2021 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above (see Note 10 - “Research and Development and License Agreements” to our unaudited financial statements filed herewith) under the October 2020 Yissum Research Agreement. Under the June 2021 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the optimization of the Liposomal Bupivacaine formulation and to increase stability for manufacturing purposes. We may terminate the agreement at any time and shall be only responsible to pay Yissum for work performed through the date of termination. In consideration for the research services, the Company agreed to pay research service fees of $337,500 in six equal quarterly installments. All services to be provided under the June 2021 Yissum Research Agreement initiated on July 1, 2021 and are anticipated to be completed towards the end 2022.
On June 29, 2021, we entered into an Agreement for Rendering of Research Services with Lipocure RX, Ltd. (the “June 2021 Lipocure Research Agreement”). Under the June 2021 Lipocure Research Agreement, the Company shall provide funding for research and development related to the optimization of the Liposomal Bupivacaine formulation and eventual manufacture of pre-clinical batches including batches for stability testing, animal studies and toxicology work. This will also include work associated with the potential filing of additional provisional patent applications. We may terminate the agreement at any time upon 30 days written notice and shall be only responsible to pay Lipocure for work performed through the date of such notice. In consideration for the research services, the Company agreed to pay research service fees of $200,000 upon execution as prepayment for research services as well as $400,000 on July, 1 2021, and five quarterly payments of $270,000 initiating on September 1 2021. The Company also agreed to pay $250,000 to Lipocure upon successful completion of Chemistry, Manufacturing and Controls (“CMC”) filing with the FDA. All services to be provided under the June 2021 Lipocure Research Agreement initiated on July 1, 2021 and are anticipated to be completed towards the end 2022. We recorded $600,000 in research and development expense for the three and nine months ended September 30, 2021 and $270,000 as a prepaid expense as of September 30, 2021 associated with this agreement.
Envelta
We believe Envelta and PES200 could support the current effort among prescribers, regulators, and patients to seek non-addictive treatment options. We plan to utilize these delivery technologies to selectively develop a portfolio of patented 505(b)(2) and NCE candidates for commercialization. The IND enabling studies for Envelta are being performed under a Cooperative Research and Development Agreement (“CRADA”) entered into by us and the National Center for Advancing Translational Sciences (“NCATS”). We intend to use these studies as a source for INDs for two additional potential indications, cancer pain and post-traumatic stress disorder. To date, two of the four planned initial in vitro studies have been successfully completed. These pre-clinical studies under the CRADA will be conducted through 2021 and 2022.
20
AnQlar
While we are currently focused on the development of our non-opioid and non-addictive pain management pipeline of product candidates, we also plan on using our proprietary delivery technologies to develop anti-viral therapies (“AnQlar”) as an anti-viral barrier to potentially prevent or reduce the risk or the intensity of viral infections in humans, including, but not limited to, influenza and SARS-CoV-2 (COVID 19). AnQlar is our patented high-density intranasal molecular masking spray being developed as an anti-viral barrier that will be used as an adjuvant to barrier-based personal protective equipment. Our results from an animal study of AnQlar demonstrated inhibited viral replication and decreased levels of virus in animal brain tissue.
We submitted and received a written pre-investigational new drug (“pre-IND”) response from the FDA for AnQlar, in its pre-IND response, the FDA provided guidance on our pathway to pursue prophylactic treatment against SARS-CoV-2 and influenza for daily use as an over-the-counter (“OTC”) product. We believe the results of the pre-IND response support further research on AnQlar as an intranasal protective that may limit transmission of the viruses to others. If we are able to successfully complete the required clinical trials for this product candidate, we intend to move forward and pursue an NDA for AnQlar as a once daily intranasal treatment. The FDA has indicated that, upon successful completion, we may pursue an NDA drug approval with the Office of Non-Prescription Drugs.
In August 2021, we engaged Syneos Health to assist with the optimal clinical trial design based on an efficient timeline.
On August 25, 2021, we entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe. The agreement with Seqens provides for both the supply material for our clinical studies as well as the long-term commercial supply of AnQlar. Seqens will conduct process development and validation of additional large scale commercial quantities of AnQlar at its facilities in Devens and Newburyport, Massachusetts.
On September 29, 2021, we engaged a research and development firm to conduct a series of IND enabling toxicity studies for AnQlar which are expected to be completed by mid-2022. Upon successful completion of these studies, we intend to submit an IND application to the FDA, including a trial design for a Phase I study as an anti-viral therapy.
On October 19, 2021, we engaged Nanomerics to supply AnQlar for our planned IND enabling toxicology studies.
VRP324
On September 17, 2021, we entered into a collaboration and license agreement with Nanomerics (the “Nanomerics License Agreement - VRP324”) for the exclusive worldwide license to develop and commercialize an investigational formulation delivered via the nasal route to enhance pharmaceutical-grade cannabidiol (“CBD”) transport to the brain to potentially treat seizures associated with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome and Dravet syndrome in patients one year of age and older. Lennox-Gastaut syndrome and Dravet syndrome are rare central nervous system diseases considered serious epileptic encephalopathies that cause different types of epileptic seizures as well as cognitive and behavioral changes and are generally resistant to treatment. Under the Nanomerics License Agreement – VRP324, we are required to make royalty payments within a range of 5% to 15% of annual net sales of royalty qualifying products. Our obligation to pay royalties, on a country-by-country basis, shall commence on the date of first commercial sale of licensed products (as defined in the Nanomerics License Agreement – VRP324) and shall expire with respect to each separate licensed product, on the latest to occur of (a) the fifteen (15th) anniversary of the first commercial sale of the first licensed product; (b) the expiration date of the last to expire of any valid claim; and, (c) the date upon which a generic product has been on the market for a period of no fewer than ninety (90) days. We paid an upfront milestone payment upon signing of $200,000 and are required to make future milestone and royalty payments of up to $41 million upon the achievement of specified development and commercial milestones, and sublicense fees for any sublicense relationships we enter into subsequent to the Nanomerics License Agreement – VRP324 (any patent that issues from the currently filed provisional patent application would expire on August 24, 2041). We have the right to terminate the Nanomerics License Agreement – VRP324 upon one hundred and eighty (180) days’ prior written notice to Nanomerics. Upon termination, we shall assign to Nanomerics all its rights, title and interest in all of its results. Nanomerics has the right to terminate the agreement upon thirty (30) days’ prior written notice if we conclude in writing to Nanomerics that the study aim has not been achieved or we notify Nanomerics that it has decided against proceeding with a Phase III Clinical trial.
21
Critical Accounting Policies and Use of Estimates
We have based our management’s discussion and analysis of financial condition and results of operations on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to clinical development expenses and stock-based compensation. We base our estimates on historical experience and on various other factors that we believe to be appropriate under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.
While our significant accounting policies are more fully discussed in Note 2 to our audited financial statements contained within our Form 10-K for the year ended December 31, 2020, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements.
Research and Development Expenses
We rely on third parties to conduct our preclinical studies and to provide services, including data management, statistical analysis and electronic compilation. Once our clinical trials begin, at the end of each reporting period, we will compare the payments made to each service provider to the estimated progress towards completion of the related project. Factors that we will consider in preparing these estimates include the number of patients enrolled in studies, milestones achieved and other criteria related to the efforts of our vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, we will record net prepaid or accrued expenses related to these costs.
Stock-Based Compensation
Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Our policy permits the valuation of stock-based awards granted to non-employees to be measured at fair value at the grant date rather than on an accelerated attribution basis over the vesting period.
Determining the appropriate fair value of share-based awards requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. We use the Black-Scholes option pricing model to value our option awards. The assumptions used in calculating the fair value of share-based awards represents management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.
The expected life of options is estimated using the simplified method, as we have historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.
22
Results of Operations
Three Months Ended September 30, 2021 and 2020
Operating expenses:
| Three Months Ended September 30, | Change | |||||||||||||||
| 2021 | 2020 | Dollars | Percentage | |||||||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative | $ | 1,551,570 | $ | 810,674 | $ | 740,896 | 91 | % | ||||||||
| Research and development | 1,698,204 | 851,780 | 846,424 | 99 | % | |||||||||||
| Total operating expenses | $ | 3,249,774 | $ | 1,662,454 | $ | 1,587,320 | 95 | % | ||||||||
General and administrative expenses increased by $740,896, or 91%, to $1,551,570 for the three months ended September 30, 2021 from $810,674 for the three months ended September 30, 2020. The primary reasons for the increase in general and administrative costs were (i) an increase in legal costs associated with litigation efforts and general corporate purposes of $634,136, (ii) an increase in insurance costs related to directors’ and officers’ insurance of $274,496, (iii) an increase in salaries and wages of $104,686 attributable to new hires, and (iv) an increase in grant consulting of $47,128. This was offset by a decrease in stock based compensation of $268,698.
Research and development expenses increased by $846,424, or 99%, to $1,698,204 for the three months ended September 30, 2021 from $851,780 for the three months ended September 30, 2020. The increase was primarily attributable to an increase in pre-clinical activities related to Epoladerm of $566,531, Probudur of $11,157, VRP324 of $200,000, and AnQlar of $83,466. This was offset by a decrease in preclinical activity and milestone payments made for Envelta of $686,637.
As a result of the foregoing, our loss from operations for the three months ended September 30, 2021 was $3,249,774, compared to a loss from operations of $1,662,454 for the three months ended September 30, 2020.
Other expenses:
| Three Months Ended September 30, | Change | |||||||||||||||
| 2021 | 2020 | Dollars | Percentage | |||||||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | $ | (28,892 | ) | $ | (45,709 | ) | $ | 16,817 | (37 | )% | ||||||
| Other income (expense) | 62,922 | - | 62,922 | 100 | % | |||||||||||
| Total other expenses: | $ | 34,030 | $ | (45,709 | ) | $ | 79,739 | (174 | )% | |||||||
Interest expense decreased by $16,817, or 37%, to $28,892 for the three months ended September 30, 2021 from $45,709 for the three months ended September 30, 2020. The decrease was primarily the result of the repayment of a convertible promissory note in February 2021.
Other income (expense) increased by $62,922 for the three months ended September 30, 2021 primarily due to the forgiveness of our PPP loan.
Nine Months Ended September 30, 2021 and 2020
Operating expenses:
| Nine Months Ended September 30, | Change | |||||||||||||||
| 2021 | 2020 | Dollars | Percentage | |||||||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative | $ | 4,814,114 | $ | 2,321,509 | $ | 2,492,605 | 107 | % | ||||||||
| Research and development | 3,089,769 | 1,187,333 | 1,902,436 | 160 | % | |||||||||||
| Total operating expenses | $ | 7,903,883 | $ | 3,508,842 | $ | 4,395,041 | 125 | % | ||||||||
23
General and administrative expenses increased by $2,492,605, or 107%, to $4,814,114 for the nine months ended September 30, 2021 from $2,321,509 for the nine months ended September 30, 2020. The primary reasons for the increase in general and administrative costs were (i) an increase in legal costs associated mainly with litigation efforts and legal costs associated with general corporate purposes of $1,891,801, (ii) an increase in insurance costs related to directors’ and officers’ insurance of $679,243, (iii) an increase in exchange listing fees of $96,958, and (iv) an increase in salaries and wages of $95,522. This was offset by a decrease in stock based compensation of $343,634 as compared to the prior period.
Research and development expenses increased by $1,902,436, or 160%, to $3,089,769 for the nine months ended September 30, 2021 from $1,187,333 for the nine months ended September 30, 2020. The increase was primarily attributable to (i) a $1,000,000 milestone payment made to Nanomerics and preclinical activity of $123,254 associated with AnQlar, (ii) increases in pre-clinical activity related to Epoladerm of $660,931, (iii) an increase in preclinical work in Probudur of $693,957, and (iv) a milestone payment of $200,000 due to VRP324. This was slightly offset by a decrease of $686,637 in pre-clinical activities associated with Envelta.
As a result of the foregoing, our loss from operations for the nine months ended September 30, 2021 was $7,903,883, compared to a loss from operations of $3,508,842 for the nine months ended September 30, 2020.
Other expenses:
| Nine Months Ended September 30, |
Change | |||||||||||||||
| 2021 | 2020 | Dollars | Percentage | |||||||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | $ | (93,640 | ) | $ | (129,600 | ) | $ | 35,960 | (28 | )% | ||||||
| Other income (expense) | 59,089 | 4,000 | 55,089 | 1,377 | % | |||||||||||
| Total other expenses: | $ | (34,551 | ) | $ | (125,600 | ) | $ | 91,049 | (72 | )% | ||||||
Interest expense decreased by $35,960, or 28%, to $93,640 for the nine months ended September 30, 2021 from $129,400 for the nine months ended September 30, 2020. The decrease was primarily the result of the repayment of a convertible promissory note in February 2021.
Other income (expense) increased by $55,089 for the nine months ended September 30, 2021 primarily due to the forgiveness of our PPP loan.
Liquidity and Capital Resources
Nine Months Ended September 30, 2021 and Year Ended December 31, 2020
Capital Resources
| September 30, | December 31, | Change | ||||||||||||||
| 2021 | 2020 | Dollars | Percentage | |||||||||||||
| Current assets | $ | 43,273,033 | $ | 73,069 | $ | 43,199,964 | 59,122 | % | ||||||||
| Current liabilities | 1,811,809 | 3,659,912 | (1,848,103 | ) | (50 | )% | ||||||||||
| Working capital | 41,461,224 | (3,586,843 | ) | 45,048,067 | (1,256 | )% | ||||||||||
As of September 30, 2021, our principal source of liquidity was our cash, which totaled $41,713,435. To continue to grow our business over the longer term, we plan to commit substantial resources to research and development, pre-clinical and clinical trials of our product candidates, other operations and potential product acquisitions and in-licensing. We have evaluated and expect to continue to evaluate a wide array of strategic transactions as part of our plan to acquire or in-license and develop additional products and product candidates to augment our internal development pipeline. Strategic transaction opportunities that we may pursue could materially affect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both. In addition, we may pursue development, acquisition or in-licensing of approved or development products in new or existing therapeutic areas or continue the expansion of our existing operations. Accordingly, we expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations, or for general corporate purposes. Strategic transactions may require us to raise additional capital through one or more public or private debt or equity financings or could be structured as a collaboration or partnering arrangement. Any equity financing would be dilutive to our stockholders. We have no arrangements, agreements, or understandings in place at the present time to enter into any acquisition, in-licensing or similar strategic business transaction.
24
Equity Financings
During the three and nine months ended September 30, 2020, we issued 10,917 and 139,220 shares of common stock for gross proceeds totaling $108,000 and $1,376,900.
On February 16, 2021, we closed an initial public offering of 1,800,000 shares of our common stock at a public offering price of $10.00 per share, for net proceeds of $15.8 million, after deducting underwriting discounts and offering expenses. We intend to use substantially all of the net proceeds from the offering to fund research and development of our Epoladerm, Probudur, Envelta and AnQlar indications and other development programs, and for working capital and other general corporate purposes.
In conjunction with our initial public offering, we amended our Certificate of Incorporation to increase the number of shares of common stock and preferred stock we are authorized to issue to 100,000,000 and 10,000,000, respectively.
On September 16, 2021, we issued 6,670,000 shares of common stock related to our underwritten offering, for net proceeds totaling $37.0 million, after deducting underwriting discounts and offering expenses. We intend to use substantially all of the net proceeds from the underwritten offering to fund research and development of all our product candidates and other development programs, the repayment of our promissory notes and deferred compensation, and for working capital and other general corporate purposes.
Debt
Promissory Notes
On October 1, 2018, we issued a promissory note, as amended (the “2018 Promissory Note”), pursuant to which we were obligated to pay Anthony Mack, our Chairman and Chief Executive Officer, the principal amount of $500,000 that bore interest at a rate of 11.19% per annum. The 2018 Promissory Note had a maturity date of the earlier of an Event of Default (as defined in the 2018 Promissory Note) and January 15, 2022. As of September 30, 2021, we had fully repaid the balance due of $500,000 on this promissory note with proceeds from the underwritten offering with accrued interest of $166,296.
On January 15, 2019, we issued a promissory note, as amended (the “2019 Promissory Note”), pursuant to which we were obligated to pay Mr. Mack the principal amount of $500,000 that bore interest at a rate of 11.19% per annum. The 2019 Promissory Note had a maturity date of the earlier of an Event of Default (as defined in the 2019 Promissory Note) and January 15, 2022. As of September 30, 2021, we had fully repaid the balance due of $500,000 on this promissory note with proceeds from the underwritten offering with accrued interest of $149,977.
In January 2021, we issued notes with an aggregate principal amount of $75,000 and $25,000, respectively. These notes were issued to Anthony Mack for $75,000 and Christopher Chipman, our Chief Financial Officer, for $25,000. These notes were subsequently repaid with proceeds from the initial public offering in February 2021.
RRD Note
On August 29, 2019, we entered into a service provider convertible note purchase agreement (the “RRD Note”) with RRD International, LLC (“RRD”). The RRD Note had a maximum principal balance of $400,000 and bore interest at a rate of 10.00% per annum and was due on March 31, 2020. During 2020, the RRD Note was amended to increase the maximum principal to $600,000 and to extend the maturity and conversion dates through to January 31, 2021. At December 31, 2020, the principal balance on the RRD Note was $493,480, with accrued interest of $34,544. In February 2021, we repaid in full the RRD Note, including accrued interest, utilizing net proceeds received from our initial public offering.
25
PPP Loan
On May 4, 2020, we entered into a promissory note (the “PPP Note”) with PNC Bank as the lender (the “Lender”), pursuant to which the Lender agreed to make a loan to us under the Paycheck Protection Program (the “PPP Loan”) offered by the U.S. Small Business Administration (the “SBA”) in a principal amount of $72,100 pursuant to Title 1 of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”).
The PPP Loan proceeds were available to be used to pay for payroll costs, including salaries, commissions, and similar compensation, group health care benefits, and paid leaves; rent; utilities; and interest on certain other outstanding debt. The amount that will be forgiven will be calculated in part with reference to our full time headcount during the period ending October 31, 2020. On July 2, 2021, we were notified by the Small Business Administration that the forgiveness amount totaled $61,816 and was recorded as other income within the statement of operations. The remaining balance of $10,284 was repaid during the quarter ended September 30, 2021.
Cash Flows
Nine Months Ended September 30, 2021 and 2020
The following table summarizes our cash flows from operating and financing activities:
| Nine Months Ended September 30, | ||||||||
| 2021 | 2020 | |||||||
| Statement of cash flow data: | ||||||||
| Total net cash provided by (used in): | ||||||||
| Operating activities | $ | (9,620,269 | ) | $ | (1,234,031 | ) | ||
| Financing activities | 51,278,908 | 1,449,000 | ||||||
| Increase in cash | $ | 41,658,639 | $ | 214,969 | ||||
Operating Activities
For the nine months ended September 30, 2021, cash used in operations was $9,620,269 compared to $1,234,031 for the nine months ended September 30, 2020. The increase in cash used in operations was primarily the result of the increase in net loss, decrease in accounts payable balances, and an increase in prepaid insurance premiums and prepaid research and development.
Financing Activities
Cash provided by financing activities was $51,278,908 during the nine months ended September 30, 2021, attributable primarily to net proceeds received from our initial public offering in February 2021 of $15,783,207 and the underwritten offering in September 2021 of $36,999,465, after deducting underwriting discounts and offering expenses. These proceeds were offset by the repayment in full of our RRD Note of $493,480 in February 2021 and repayments of our promissory notes and PPP loan of an aggregate of $1,503,764. Cash provided by financing activities was $1,449,000 during the nine months ended September 30, 2020, attributable to $1,376,900 from the sale of 139,220 shares of our common stock as well as proceeds received from our PPP loan of $72,100.
Future Capital Requirements
We expect that our existing cash will be sufficient to fund our operations, future research and development, and general working capital through at least one year from the issuance of its financial statements. However, it is difficult to predict our spending for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cash significantly faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstances beyond our control.
26
Our expectations regarding future cash requirements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we make in the future. We have no current understandings, agreements or commitments for any material acquisitions or licenses of any products, businesses or technologies. We may need to raise substantial additional capital in order to engage in any of these types of transactions.
We expect to continue to incur substantial additional operating losses for at least the next several years as we continue to develop our product candidates and seek marketing approval and, subject to obtaining such approval, the eventual commercialization of our product candidates. If we obtain marketing approval for our product candidates, we will incur significant sales, marketing and outsourced manufacturing expenses. In addition, we expect to incur additional expenses to add operational, financial and information systems and personnel, including personnel to support our planned product commercialization efforts. We also expect to continue to incur significant costs to comply with corporate governance, internal controls and similar requirements applicable to us as a public company.
Our future use of operating cash and capital requirements will depend on many forward-looking factors, including the following:
| ● | the initiation, progress, timing, costs and results of clinical trials for our product candidates; |
| ● | the clinical development plans we establish for each product candidate; |
| ● | the number and characteristics of product candidates that we develop or may in-license; |
| ● | the terms of any collaboration agreements we may choose to execute; |
| ● | the outcome, timing and cost of meeting regulatory requirements established by the U.S. Drug Enforcement Administration, the FDA, the European Medicines Agency or other comparable foreign regulatory authorities; |
| ● | the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; |
| ● | the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us; |
| ● | costs and timing of the implementation of commercial scale manufacturing activities; |
| ● | the cost of establishing, or outsourcing, sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; and |
| ● | the costs to defend litigation; |
To the extent that our capital resources are insufficient to meet our future operating and capital requirements, we must finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. We have no committed external sources of funds. Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.
If we raise additional funds by issuing equity securities, our stockholder will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation and other preferences that are not favorable to us or our stockholder. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us.
Liquidity
Since inception, we have been engaged in organizational activities, including raising capital and research and development activities. We have not generated revenues and has not yet achieved profitable operations, nor have we ever generated positive cash flow from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. We are subject to those risks associated with any preclinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that our research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, we operate in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, our future operations are dependent on the success of our efforts to raise additional capital.
27
We incurred a net loss of $7,938,434 and $3,634,442 for the nine months ended September 30, 2021 and 2020, respectively, and had an accumulated deficit of $18,586,278 as of September 30, 2021. We anticipate incurring additional losses until such time, if ever, that we can generate significant revenue from our product candidates currently in development. Our primary source of capital has been the issuance of debt and equity securities. We closed our initial public offering in February 2021 and offering in September 2021, raising net proceeds of $15,783,207 and $36,999,465, respectively. Our cash on hand as of September 30, 2021 was $41,713,435.
Management believes that current cash, including the proceeds from our initial public offering and the underwritten offering in September 2021, is sufficient to fund operations and capital requirements into 2024. Additional financings will be needed by us to fund our operations, to complete clinical development of and to commercially develop our product candidates. There is no assurance that such financing will be available when needed or on acceptable terms. We also have the ability to curtail spending in research and development activities in order to conserve cash.
Global Pandemic Outbreak
In March 2020, the World Health Organization declared COVID-19 a global pandemic. The outbreak has become increasingly widespread in the United States, impacting the markets in which we operate. While the full impact of the pandemic continues to evolve, the financial markets have been subject to significant volatility that adversely impacts our ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset values also affect our ability to enter into collaborations, joint ventures, and license and royalty agreements. The outbreak and government measures taken in response to the pandemic have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, have spiked, while demand for other goods and services, such as travel, have fallen. The future progression of the pandemic and its effects on our business and operations are uncertain. We may face difficulties recruiting or retaining patients in our ongoing and planned preclinical and clinical trials if patients are affected by the virus or are fearful of traveling to our clinical trial sites because of the outbreak. We and our third-party contract manufacturers, CROs, and clinical sites may also face disruptions in procuring items and materials that are essential to our research and development activities, including, for example, clinical trial drug products, medical and laboratory supplies used in our clinical trials or preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak. While expected to be temporary, these disruptions may negatively impact our results of operations, financial condition, and liquidity in 2021, and potentially beyond.
Factors that May Affect Future Results
You should refer to Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2020 for a discussion of important factors that may affect our future results.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements, as defined by applicable SEC regulations.
Discussion of Critical Accounting Policies and Significant Judgments and Estimates
The preparation of financial statements in conformity with U.S. GAAP requires us to use judgment in making certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in our financial statements and accompanying notes. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require difficult, subjective and complex judgments by management in order to make estimates about the effect of matters that are inherently uncertain. During the nine months ended September 30, 2021, there were no significant changes to our critical accounting policies from those described in our annual financial statements for the year ended December 31, 2020, which we included in our Annual Report on Form 10-K for the year ended December 31, 2020.
28
ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
Item 4: Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2021. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Evaluation of Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the period to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. From time to time, we make changes to our internal control over financial reporting that are intended to enhance its effectiveness and which do not have a material effect on our overall internal control over financial reporting.
As a newly public company, we continue the process of reviewing and documenting our disclosure controls and procedures, including our internal controls and procedures for financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.
29
part II – Other information
ITEM 1: LEGAL PROCEEDINGS
On March 12, 2021, we and Mr. Mack (the “Defendants”) were named as defendants in a complaint (the “Complaint”) filed by Sorrento Therapeutics, Inc. (“Sorrento”), and Scilex Pharmaceuticals Inc. (“Scilex” and together with Sorrento, the “Plaintiffs”) in the Court of Chancery of the State of Delaware. In the Complaint, the Plaintiffs alleged (i) Mr. Mack breached a Restrictive Covenants Agreement, dated as of November 8, 2016, between himself and Sorrento (the “Restrictive Covenants Agreement”), (ii) the Company tortiously interfered with the Restrictive Covenants Agreement, and (iii) the Company tortiously interfered with Scilex’s relationship with Mr. Mack. On May 7, 2021 Plaintiffs filed an Amended Complaint (the “First Amended Complaint”) asserting the same three causes of action. Simultaneously with filing the original Complaint, Plaintiffs filed a motion to expedite, seeking a hearing on their prospective motion for a preliminary injunction, prohibiting Mr. Mack’s alleged violations of the Restrictive Covenants Agreement and prohibiting the alleged tortious interference. On March 22, 2021, Vice Chancellor Paul A. Fioravanti Jr. issued a scheduling order, setting forth terms which had been agreed to by the parties, under which oral argument on Plaintiffs’ proposed motion for preliminary injunction was scheduled for July 15, 2021. On May 18, 2021, the Vice Chancellor issued a revised scheduling order, also setting forth terms which had been agreed to by the parties, under which Plaintiffs agreed not to move for a preliminary injunction and a trial in the action was set for February 9-11, 2022. On September 28, 2021, Plaintiffs filed a Second Amended Verified Complaint asserting the same three causes of action as the prior complaints, as well as additional claims in which Plaintiffs allege (i) Mr. Mack breached an Employment, Proprietary Information and Inventions Agreement, dated as of October 25, 2016, between himself and Sorrento (the “Employment Agreement”), (ii) the Company tortiously interfered with the Employment Agreement, (iii) Mr. Mack breached his fiduciary duties to Scilex, and (iv) the Company aided and abetted Mr. Mack’s alleged breach of fiduciary duties to Scilex. On October 18, 2021, Defendants filed an Answer to the Second Amended Complaint, and subsequently withdrew a previously filed motion to dismiss the first Amended Complaint. We intend to vigorously defend the action. However, we are unable to predict the ultimate outcome of the lawsuit at this time.
ITEM 1A: RISK FACTORS
Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 31, 2021. There have been no other material changes to our risk factors since the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
ITEM 2: UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Unregistered Sales of Equity Securities
None.
Use of Proceeds from Registered Securities
On February 16, 2021, our registration statement on Form S-1 (Registration No. 333-249417) was declared effective by the SEC for our initial public offering pursuant to which we sold an aggregate of 1,800,000 shares of our Common Stock at a price to the public of $10.00 per share, for an aggregate offering of approximately $18.0 million. ThinkEquity, a division of Fordham Financial Management, Inc. acted as the sole book-running manager for the offering. On February 19, 2021, we closed the sale of 1,800,000 shares of Common Stock, resulting in net proceeds to us of approximately $16.0 million after deducting underwriting discounts and commissions and other offering expenses. No payments were made by us to directors, officers or persons owning ten percent or more of our Common Stock or to their associates, or to our affiliates. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on February 18, 2021 pursuant to Rule 424(b).
ITEM 3: DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4: MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5: OTHER INFORMATION
None.
30
ITEM 6: EXHIBITS
| Exhibit No. | Description | |
| 31.1* | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a). | |
| 31.2* | Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a). | |
| 32.1** | ||
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| * | Filed herewith. |
| ** | Furnished, not filed. |
| † | Indicates a management contract or compensation plan, contract or arrangement. |
31
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on November 15, 2021.
| VIRPAX PHARMACEUTICALS, INC. | ||
| Date: November 15, 2021 | By: | /s/ Anthony P. Mack |
| Anthony P. Mack | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| /s/ Christopher Chipman | ||
| Christopher Chipman | ||
| Chief Financial Officer | ||
| (Principal Financial Officer and Principal Accounting Officer) | ||
32
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Anthony Mack, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Virpax Pharmaceuticals, Inc. (the “Registrant”); |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report; |
| 4. | The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have: |
| a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c) | evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and |
| 5. | The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions): |
| a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and |
| b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting. |
| Date: November 15, 2021 | /s/ Anthony P. Mack |
| Anthony P. Mack | |
| President and Chief Executive Officer | |
| (Principal Executive Officer) |
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Christopher Chipman, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Virpax Pharmaceuticals, Inc. (the “Registrant”); |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report; |
| 4. | The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have: |
| a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c) | evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and |
| 5. | The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions): |
| a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and |
| b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting. |
| Date: November 15, 2021 | /s/ Christopher Chipman |
| Christopher Chipman | |
| Chief Financial Officer | |
| (Principal Financial and Accounting Officer) |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Virpax Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of Anthony Mack, as Chief Executive Officer, and Christopher Chipman, as Chief Financial Officer, certifies in his capacity as such officer of the Company, that to such officer’s knowledge, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: November 15, 2021
| By: | /s/ Anthony P. Mack | |
| Anthony P. Mack | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| By: | /s/ Christopher Chipman | |
| Christopher Chipman | ||
| Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) |
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.
Condensed Balance Sheets (Parentheticals) - $ / shares |
Sep. 30, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Statement of Financial Position [Abstract] | ||
| Preferred stock par value (in Dollars per share) | $ 0.00001 | $ 0.00001 |
| Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
| Preferred stock, shares issued | ||
| Preferred stock, shares outstanding | ||
| Common stock, par value (in Dollars per share) | $ 0.00001 | $ 0.00001 |
| Common stock, shares authorized | 100,000,000 | 100,000,000 |
| Common stock, shares issued | 11,715,182 | 3,145,153 |
| Common stock, shares outstanding | 11,715,182 | 3,145,153 |
Condensed Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2021 |
Sep. 30, 2020 |
Sep. 30, 2021 |
Sep. 30, 2020 |
|
| OPERATING EXPENSES | ||||
| General and administrative | $ 1,551,570 | $ 810,674 | $ 4,814,114 | $ 2,321,509 |
| Research and development | 1,698,204 | 851,780 | 3,089,769 | 1,187,333 |
| Total operating expenses | 3,249,774 | 1,662,454 | 7,903,883 | 3,508,842 |
| Loss from operations | (3,249,774) | (1,662,454) | (7,903,883) | (3,508,842) |
| OTHER (EXPENSE) INCOME | ||||
| Interest expense | (28,892) | (45,709) | (93,640) | (129,600) |
| Other income (expense), net | 62,922 | 59,089 | 4,000 | |
| Loss before tax provision | (3,215,744) | (1,708,163) | (7,938,434) | (125,600) |
| Benefit from income taxes | ||||
| Net loss | $ (3,215,744) | $ (1,708,163) | $ (7,938,434) | $ (3,634,442) |
| Basic and diluted net loss per share (in Dollars per share) | $ (0.53) | $ (0.54) | $ (1.59) | $ (1.18) |
| Basic and diluted weighted average common stock outstanding (in Shares) | 6,011,796 | 3,142,090 | 4,979,553 | 3,091,108 |
Condensed Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited) - USD ($) |
Preferred stock |
Common stock |
Additional paid-in capital |
Accumulated deficit |
Total |
|||
|---|---|---|---|---|---|---|---|---|
| Balance at Dec. 31, 2019 | $ 30 | $ 3,575,886 | $ (6,308,191) | $ (2,732,275) | ||||
| Balance (in Shares) at Dec. 31, 2019 | 3,018,673 | |||||||
| Common stock issued pursuant to subscription agreements | 425,000 | 425,000 | ||||||
| Common stock issued pursuant to subscription agreements (in Shares) | 42,978 | |||||||
| Common stock issued in payment of consulting services and settlement of accounts payable | 1,781 | 1,781 | ||||||
| Common stock issued in payment of consulting services and settlement of accounts payable (in Shares) | 180 | |||||||
| Stock-based compensation | 130,990 | 130,990 | ||||||
| Restricted stock awards granted | ||||||||
| Restricted stock awards granted (in Shares) | 3,792 | |||||||
| Net loss | (656,495) | (656,495) | ||||||
| Balance at Mar. 31, 2020 | $ 30 | 4,133,657 | (6,964,686) | (2,830,999) | ||||
| Balance (in Shares) at Mar. 31, 2020 | 3,065,623 | |||||||
| Common stock issued pursuant to subscription agreements | $ 1 | 843,899 | 843,900 | |||||
| Common stock issued pursuant to subscription agreements (in Shares) | 85,325 | |||||||
| Common stock issued in payment of consulting services and settlement of accounts payable | 1,125 | 1,125 | ||||||
| Common stock issued in payment of consulting services and settlement of accounts payable (in Shares) | 113 | |||||||
| Stock-based compensation | 571,691 | 571,691 | ||||||
| Restricted stock awards granted | ||||||||
| Restricted stock awards granted (in Shares) | 3,160 | |||||||
| Restricted stock awards forfeited | ||||||||
| Restricted stock awards forfeited (in Shares) | (20,225) | |||||||
| Net loss | (1,269,784) | (1,269,784) | ||||||
| Balance at Jun. 30, 2020 | $ 31 | 5,550,372 | (8,234,470) | (2,684,067) | ||||
| Balance (in Shares) at Jun. 30, 2020 | 3,133,996 | |||||||
| Common stock issued pursuant to subscription agreements | 108,000 | 108,000 | ||||||
| Common stock issued pursuant to subscription agreements (in Shares) | 10,917 | |||||||
| Common stock issued in payment of consulting services and settlement of accounts payable | 2,382 | 2,382 | ||||||
| Common stock issued in payment of consulting services and settlement of accounts payable (in Shares) | 240 | |||||||
| Stock-based compensation | 435,415 | 435,415 | ||||||
| Net loss | (1,708,163) | (1,708,163) | ||||||
| Balance at Sep. 30, 2020 | $ 31 | 6,096,169 | (9,942,633) | (3,846,433) | ||||
| Balance (in Shares) at Sep. 30, 2020 | 3,145,153 | |||||||
| Balance at Dec. 31, 2020 | $ 31 | 6,431,715 | (10,647,844) | (4,216,098) | [1] | |||
| Balance (in Shares) at Dec. 31, 2020 | 3,145,153 | |||||||
| Common stock issued pursuant to initial public offering, net of offering costs of $2,216,793 | $ 18 | 15,783,189 | 15,783,207 | |||||
| Common stock issued pursuant to initial public offering, net of offering costs of $2,216,793 (in Shares) | 1,800,000 | |||||||
| Stock-based compensation | 369,884 | 369,884 | ||||||
| Net loss | (2,379,271) | (2,379,271) | ||||||
| Balance at Mar. 31, 2021 | $ 49 | 22,584,788 | (13,027,115) | 9,557,722 | ||||
| Balance (in Shares) at Mar. 31, 2021 | 4,945,153 | |||||||
| Stock-based compensation | 321,427 | 321,427 | ||||||
| Restricted stock awards granted | $ 1 | (1) | ||||||
| Restricted stock awards granted (in Shares) | 15,000 | |||||||
| Net loss | (2,343,419) | (2,343,419) | ||||||
| Balance at Jun. 30, 2021 | $ 50 | 22,906,214 | (15,370,534) | 7,535,730 | ||||
| Balance (in Shares) at Jun. 30, 2021 | 4,960,153 | |||||||
| Common stock issued pursuant to secondary offering, net of expenses | $ 67 | 36,999,398 | 36,999,465 | |||||
| Common stock issued pursuant to secondary offering, net of expenses (in Shares) | 6,670,000 | |||||||
| Cashless exercise of stock options and warrants | ||||||||
| Cashless exercise of stock options and warrants (in Shares) | 85,669 | |||||||
| Stock-based compensation | 141,773 | 141,773 | ||||||
| Restricted stock awards forfeited | ||||||||
| Restricted stock awards forfeited (in Shares) | (640) | |||||||
| Net loss | (3,215,744) | (3,215,744) | ||||||
| Balance at Sep. 30, 2021 | $ 117 | $ 60,047,385 | $ (18,586,278) | $ 41,461,224 | ||||
| Balance (in Shares) at Sep. 30, 2021 | 11,715,182 | |||||||
| ||||||||
Condensed Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited) (Parentheticals) |
3 Months Ended |
|---|---|
|
Mar. 31, 2021
USD ($)
| |
| Statement of Stockholders' Equity [Abstract] | |
| Offering cost, net | $ 2,216,793 |
Condensed Statements of Cash Flows (Unaudited) - USD ($) |
9 Months Ended | |
|---|---|---|
Sep. 30, 2021 |
Sep. 30, 2020 |
|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $ (7,938,434) | $ (3,634,442) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Non-cash interest expense | 129,600 | |
| Forgiveness of PPP loan | (61,816) | |
| Stock-based compensation | 833,084 | 1,138,096 |
| Common stock issued in payment of consulting services and settlement of accounts payable | 5,288 | |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (999,685) | (12,873) |
| Accounts payable and accrued expenses | (1,453,418) | 1,140,300 |
| Net cash used in operating activities | (9,620,269) | (1,234,031) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Repayment of notes payable | (503,764) | |
| Proceeds from the issuance of debt | 72,100 | |
| Proceeds from related party notes payable | 100,000 | |
| Repayment of related party notes payable | (1,100,000) | |
| Proceeds from the issuance of stock | 1,376,900 | |
| Offering costs related to secondary offering | (3,020,535) | |
| Proceeds from secondary offering of common stock | 40,020,000 | |
| Offering costs related to initial public offering | (2,216,793) | |
| Proceeds from initial public offering of common stock | 18,000,000 | |
| Net cash provided by financing activities | 51,278,908 | 1,449,000 |
| Net change in cash | 41,658,639 | 214,969 |
| Cash, beginning of period | 54,796 | 41,536 |
| Cash, end of period | 41,713,435 | 256,505 |
| Supplemental disclosure of cash and non-cash financing activities | ||
| Cash paid for interest | 363,640 | |
| Cash paid for taxes | ||
| Common stock issued in payment of consulting services and settlements of accounts payable | 5,288 | |
| Deferred financing costs, included in accounts payable and accrued expenses | 176,391 | |
| Debt issued in payment of consulting services and settlement of accounts payable | $ 228,960 | |
Business and Liquidity |
9 Months Ended |
|---|---|
Sep. 30, 2021 | |
| Business and Liquidity [Abstract] | |
| Business and Liquidity | Note 1. Business and Liquidity
Business
Virpax Pharmaceuticals, Inc. (“Virpax” or the “Company”) was incorporated on May 12, 2017 in the state of Delaware. Virpax is a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems. Virpax has exclusive global rights to a proprietary patented Topical Spray Film Delivery Technology for osteoarthritis pain (“Epoladerm”). Virpax also has exclusive global rights to a proprietary patented injectable “local anesthetic” Liposomal Gel Technology for postoperative pain management (“Probudur”). Additionally, Virpax has exclusive global rights to a proprietary patented Nanomerics’ Molecular Envelope Technology (“MET”) that uses an intranasal device to deliver enkephalin for the management of acute and chronic pain, including pain associated with cancer (“NES100”). NES100 would support the current effort among prescribers, regulators, and patients to seek non-opioid and non-addictive treatment options to combat the opioid epidemic. Virpax will utilize these delivery technologies to selectively develop a portfolio of patented 505(b)(2) and new chemical entity (“NCE”) candidates for commercialization. While the Company is currently focused on the development of its non-opioid and non-addictive pain management pipeline of product candidates, the Company also plans on using its proprietary delivery technologies to develop anti-viral therapies (“AnQlar”) as an anti-viral barrier to potentially prevent or reduce the risk or the intensity of viral infections in humans, including, but not limited to, influenza and SARS-CoV-2 (COVID 19).
The Company, since inception, has been engaged in organizational activities, including raising capital and research and development activities. The Company has not generated revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flow from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any preclinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.
The Company incurred a net loss of $7,938,434 and $3,634,442 for the nine months ended September 30, 2021 and 2020, respectively, and had an accumulated deficit of $18,586,278 as of September 30, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of debt and equity securities.
On February 16, 2021, the Company announced the pricing of its initial public offering (the “IPO”) of 1,800,000 shares of its common stock at an initial offering price of $10.00 per share. The Company’s common stock commenced trading on the NASDAQ on February 17, 2021 under the ticker symbol “VRPX”. The IPO closed on February 19, 2021. The gross proceeds from the IPO were $18.0 million. The net proceeds of the IPO were approximately $15.8 million after deducting underwriting discounts, commissions and offering expenses payable by the Company, including offering costs paid and offering costs accrued and unpaid as of December 31, 2020. In conjunction with the IPO, the Company granted the underwriters warrants to purchase 90,000 shares of Company common stock at an exercise price of $12.50 per share, which is 125% of the initial public offering price.
On September 16, 2021, the Company announced the closing of an underwritten public offering of 6,670,000 shares of its common stock at a price of $6.00 per share (the “Underwritten Public Offering”). The gross proceeds from the Underwritten Public Offering were $40.0 million. The net proceeds of the Underwritten Public Offering were approximately $37.0 million after deducting underwriting discounts, commissions and offering expenses payable by the Company.
In addition, with respect to the ongoing and evolving coronavirus (“COVID-19”) outbreak, which was designated as a pandemic by the World Health Organization on March 11, 2020, the outbreak has caused substantial disruption in international and U.S. economies and markets and if repercussions of the outbreak are prolonged, could have a significant adverse impact on the Company’s business.
Management believes that current cash, including the proceeds from our initial public offering and the underwritten offering in September 2021, is sufficient to fund operations and capital requirements into 2024. Additional financings will be needed by the Company to fund its operations, to complete clinical development of and to commercially develop all of its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms. The Company also has the ability to curtail spending in research and development activities in order to conserve cash. |
Summary of Significant Accounting Policies |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Significant Accounting Policies | Note 2. Summary of Significant Accounting Policies
Basis of Presentation — The interim condensed financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation of the financial position of Virpax at September 30, 2021, and its results of operations and its cash flows for the three and nine months ended September 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the years ended December 31, 2020 and 2019 and notes thereto. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations of the Securities and Exchange Commission (“SEC”) relating to interim financial statements. The December 31, 2020 balance sheet information was derived from the audited financial statements as of that date.
Use of Estimates — The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.
Significant items subject to such estimates and assumptions include research and development accruals and the valuation of stock-based compensation. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.
Basic and Diluted Loss per Share — Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an antidilutive effect. Equivalent common shares excluded from the calculation of diluted net loss per share since their effect is antidilutive due to the net loss of the Company consisted of the following:
Cash — At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. Total cash was $41,713,435 and $54,796 as of September 30, 2021 and December 31, 2020, respectively.
Fair Value of Financial Instruments — The carrying amounts of the Company’s financial instruments, including cash and accounts payable approximate fair value due to the short-term nature of those instruments.
Research and Development — Research and development costs are expensed as incurred. These expenses include the costs of proprietary efforts, as well as costs incurred in connection with certain licensing arrangements and external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available.
Stock-based Compensation — Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. The Company’s policy permits the valuation of stock-based awards granted to non-employees to be measured at fair value at the grant date rather than on an accelerated attribution basis over the vesting period.
Determining the appropriate fair value of share-based awards requires the use of subjective assumptions, including the fair value of the Company’s common shares, and for options, the expected life of the option and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represents management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.
The expected life of options was estimated using the simplified method, as the Company has historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.
Income Taxes — The Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods.
The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of September 30, 2021, the Company had no uncertain income tax positions. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prepaid Expenses and Other Current Assets |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prepaid Expenses and Other Current Assets [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prepaid Expenses and Other Current Assets | Note 3. Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consists of the following:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Payable and Accrued Liabilities |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Payables and Accruals [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Payable and Accrued Liabilities | Note 4. Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consists of the following:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes Payable | Note 5. Notes Payable
On October 1, 2018, the Company entered into a promissory note (the “2018 Promissory Note”), which promised to pay Anthony Mack, Chief Executive Officer and significant investor, the principal amount of $500,000, and bore interest at a rate of 11.19% per annum. The 2018 Promissory Note stated that the principal was due at the earlier of an event of default (as defined in the 2018 Promissory Note) and the first anniversary of the date of the 2018 Promissory Note. As of September 30, 2021, the Company had fully repaid the balance due of $500,000 on this promissory note with accrued interest of $166,296.
On January 15, 2019, the Company entered into a promissory note (the “2019 Promissory Note”), which promised to pay Anthony Mack the principal amount of $500,000, and bore interest at a rate of 11.19% per annum. The 2019 Promissory Note stated that the principal was due at the earlier of an event of default (as defined in the 2019 Promissory Note) and the first anniversary of the date of the 2019 Promissory Note. On April 6, 2020, the Company and Anthony Mack entered into an amendment to the 2019 Promissory Note which extended the maturity date from the first anniversary of the date of the 2019 Promissory Note to January 15, 2021, with all other terms remaining consistent. As of September 30, 2021, the Company had fully repaid the balance due of $500,000 on this promissory note with accrued interest of $149,977.
In January 2021, the Company issued notes with an aggregate principal amount of $75,000 and $25,000, respectively. These notes were issued to Anthony Mack for $75,000 and Christopher Chipman, Chief Financial Officer, for $25,000. These notes bore interest as a rate of 1.35% per annum and were subsequently fully repaid with proceeds from the IPO, including accrued interest of $122 and $41, respectively.
On August 29, 2019, the Company entered into a service provider convertible note purchase agreement (the “RRD Note”) with RRD International, LLC (“RRD”). Under the RRD Note, the Company and RRD agreed to make certain compensation due to RRD payable in the form of a convertible promissory note. The RRD Note stated that a maximum principal balance of $400,000 could be applied for services provided by RRD to the Company, which could be converted into equity or cash (all or in part) upon a Qualified Financing (as defined in the RRD Note) or the Conversion Date of March 31, 2020. Borrowings under the RRD Note bore simple interest on the outstanding principal amount of the RRD Note until paid in full at the fixed rate of 10% per annum. During 2020, the RRD Note was amended to increase the maximum principal to $600,000 and to extend the maturity and conversion dates through to January 31, 2021. As of December 31, 2020, the balance on the RRD Note was $493,480, with accrued interest of $34,544.
In February 2021, the Company fully paid the balance on its RRD Note of $528,024, including $34,544 of accrued interest, with proceeds from the Company’s IPO.
On May 4, 2020, the Company entered into a Promissory Note (the “PPP Note”) with PNC Bank as the lender (the “Lender”), pursuant to which the Lender agreed to make a loan to the Company under the Paycheck Protection Program (the “PPP Loan”) offered by the U.S. Small Business Administration (the “SBA”) in a principal amount of $72,100 pursuant to Title 1 of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”). The PPP Loan proceeds are available to be used to pay for payroll costs, including salaries, commissions, and similar compensation, group health care benefits, and paid leaves; rent; utilities; and interest on certain other outstanding debt. The amount that will be forgiven will be calculated in part with reference to the Company’s full time headcount during the period ending October 31, 2020. The interest rate on the PPP Note is a fixed rate of 1% per annum. To the extent that the amounts owed under the PPP Loan, or a portion of them, are not forgiven, the note shall convert to an amortizing term loan and the Company will be required to make principal and interest payments in monthly installments beginning seven months from April 2020. The PPP Note matures in two years. The PPP Note includes events of default. Upon the occurrence of an event of default, the Lender will have the right to exercise remedies against us, including the right to require immediate payment of all amounts due under the PPP Note. On July 2, 2021, the SBA notified the Company that the forgiveness amount totaled $61,816 and was recorded as other income within the statement of operations. The remaining balance of $10,284 was fully repaid by the Company during the quarter ended September 30, 2021.
The following table summarizes the Company’s notes payables:
Interest expense was $93,640 and $129,600 for the nine months ended September 30, 2021 and 2020, respectively. Interest expense was $28,892 and $45,709 for the three months ended September 30, 2021 and 2020, respectively. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies |
9 Months Ended |
|---|---|
Sep. 30, 2021 | |
| Commitments and Contingencies Disclosure [Abstract] | |
| Commitments and Contingencies | Note 6. Commitments and Contingencies
Employment Agreements
The Company has an employment agreement with Anthony Mack, the Company’s Chief Executive Officer (“CEO”), effective September 18, 2018. The agreement may be terminated by either party at any time upon written notice provided to the other party. Concurrent with the employment agreement, the CEO and the Company agreed to an Executive Confidentiality Agreement that contains standard non-closure and non-competition provisions. In the event we terminate the employment agreement other than for cause, or the CEO terminates the agreement for good reason, we will pay the CEO the then effective base salary for a period of twelve months following the effective date of the termination. However, payment of the effective base salary is subject to the execution of a release form and the compliance by the CEO with the release and all terms and provisions of the employment agreement and Executive Confidentiality Agreement that survive the termination of employment. The Company’s Chief Executive Officer also elected to defer salary temporarily. Deferred compensation due to the Company’s Chief Executive Officer amounted to $0 and $1,005,000 as of September 30, 2021 and December 31, 2020, respectively, which is included in accounts payable and accrued expenses on the accompanying condensed balance sheets. In March 2021, the Company’s Chief Executive Officer ceased deferring compensation.
Litigation
From time to time the Company is subject to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.
On March 12, 2021, the Company and Mr. Mack (the “Defendants”) were named as defendants in a complaint (the “Complaint”) filed by Sorrento Therapeutics, Inc. (“Sorrento”), and Scilex Pharmaceuticals Inc. (“Scilex” and together with Sorrento, the “Plaintiffs”) in the Court of Chancery of the State of Delaware. In the Complaint, the Plaintiffs alleged (i) Mr. Mack breached a Restrictive Covenants Agreement, dated as of November 8, 2016, between himself and Sorrento (the “Restrictive Covenants Agreement”), (ii) the Company tortiously interfered with the Restrictive Covenants Agreement, and (iii) the Company tortiously interfered with Scilex’s relationship with Mr. Mack. On May 7, 2021 Plaintiffs filed an Amended Complaint (the “First Amended Complaint”) asserting the same three causes of action. Simultaneously with filing the original Complaint, Plaintiffs filed a motion to expedite, seeking a hearing on their prospective motion for a preliminary injunction, prohibiting Mr. Mack’s alleged violations of the Restrictive Covenants Agreement and prohibiting the alleged tortious interference. On March 22, 2021, Vice Chancellor Paul A. Fioravanti Jr. issued a scheduling order, setting forth terms which had been agreed to by the parties, under which oral argument on Plaintiffs’ proposed motion for preliminary injunction was scheduled for July 15, 2021. On May 18, 2021, the Vice Chancellor issued a revised scheduling order, also setting forth terms which had been agreed to by the parties, under which Plaintiffs agreed not to move for a preliminary injunction and a trial in the action was set for February 9-11, 2022. On September 28, 2021, Plaintiffs filed a Second Amended Verified Complaint asserting the same three causes of action as the prior complaints, as well as additional claims in which Plaintiffs allege (i) Mr. Mack breached an Employment, Proprietary Information and Inventions Agreement, dated as of October 25, 2016, between himself and Sorrento (the “Employment Agreement”), (ii) the Company tortiously interfered with the Employment Agreement, (iii) Mr. Mack breached his fiduciary duties to Scilex, and (iv) the Company aided and abetted Mr. Mack’s alleged breach of fiduciary duties to Scilex. On October 18, 2021, Defendants filed an Answer to the Second Amended Complaint, and subsequently withdrew a previously filed motion to dismiss the first Amended Complaint. We intend to vigorously defend the action. However, we are unable to predict the ultimate outcome of the lawsuit at this time.
Global Pandemic Outbreak
In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (“COVID-19”) a global pandemic. The outbreak has become increasingly widespread in the United States, impacting the markets in which the Company operates. While the full impact of the pandemic continues to evolve, the financial markets have been subject to significant volatility that adversely impacts the Company’s ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset values also affect the Company’s ability to enter into collaborations, joint ventures, and license and royalty agreements. The outbreak and government measures taken in response to the pandemic have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, have spiked, while demand for other goods and services, such as travel, have fallen. The future progression of the outbreak and its effects on our business and operations are uncertain. We may face difficulties recruiting or retaining patients in our ongoing and planned clinical trials if patients are affected by the virus or are fearful of traveling to our clinical trial sites because of the outbreak. We and our third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to our research and development activities, including, for example, medical and laboratory supplies used in our clinical trials or preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak.
While expected to be temporary, these disruptions may negatively impact the Company’s results of operations, financial condition, and liquidity in 2021 and potentially beyond. |
Stockholders' Equity |
9 Months Ended |
|---|---|
Sep. 30, 2021 | |
| Stockholders' Equity Note [Abstract] | |
| Stockholders' Equity | Note 7. Stockholders’ Equity
Overview
Preferred Stock
The Company’s Certificate of Incorporation, filed on May 12, 2017, and amended and restated on February 16, 2021, authorizes the issuance of preferred stock. The total number of shares which the Company is authorized to issue is 10,000,000, with a par value of $0.00001 per share.
Common Stock
The Company’s Certificate of Incorporation, filed on May 12, 2017, and amended and restated on February 16, 2021, authorizes the issuance of common stock. The total number of shares which the Company is authorized to issue is 100,000,000, with a par value of $0.00001 per share.
On February 19, 2021, the Company issued 1,800,000 shares of common stock related to the Company’s IPO, for net proceeds totaling $15,783,207, after deducting underwriting discounts and offering expenses. On September 16, 2021, the Company issued 6,670,000 shares of common stock related to the Company’s Underwritten Public Offering, for net proceeds totaling $36,999,465, after deducting underwriting discounts and offering expenses.
During the three and nine months ended September 30, 2020, the Company issued 10,917 and 139,220 shares of common stock for gross proceeds totaling $108,000 and $1,376,900, respectively. Anthony Mack, the Company’s CEO, and an immediate family member of Mr. Mack, purchased 40,450 and 8,999 of these shares of common stock for gross proceeds totaling $400,000 and $89,000, respectively, for the nine months ended September 30, 2020. There were no such purchases by the CEO and immediate family member during the three and nine months ended September 30, 2021. Also, the Company issued 45,448 shares of the Company’s common stock upon the exercise of 87,751 options in a cashless exercise during the three months ended September 30, 2021.
In addition, during the three and nine months ended September 30, 2020, the Company issued 240 and 533 shares of common stock in payment of consulting services and settlement of accounts payable totaling $2,382 and $5,288, respectively.
Warrants
In conjunction with the IPO, the Company granted the underwriters warrants to purchase 90,000 shares of the Company’s common stock at an exercise price of $12.50 per share, which is 125% of initial public offering price. The warrants have a five-year term and are not exercisable prior to August 16, 2021. The fair value allocated to the warrants of $639,000 was accounted for as a component of stockholders’ equity. The fair value of the warrants was estimated using the Black-Scholes option-pricing model and is affected by the Company’s share fair value as well as assumptions regarding a number of complex and subjective variables, including a term of 5 years, expected price volatility of 100%, and a risk-free interest rate of 0.6%.
The Company issued 40,221 shares of the Company’s common stock upon the exercise of 76,620 warrants in a cashless exercise during the three months ended September 30, 2021. There were warrants to purchase 18,436 shares of the Company’s common stock outstanding at September 30, 2021.
Reverse Stock Split
On November 19, 2020, the Company filed an amendment to its Articles of Incorporation and effected 1-for-4.944260256 reverse stock split of its issued and outstanding shares of common stock, $0.00001 par value, whereby 15,550,627 outstanding shares of the Company’s common stock were exchanged for 3,145,153 newly issued shares of the Company’s common stock. Under the terms of the reverse stock split, fractional shares issuable to stockholders were rounded to the nearest whole share, with cash paid in lieu of any fractional shares, resulting in a reverse split of 1-for-4.944260256. All per share amounts and number of shares (other than authorized shares) in the financial statements and related notes have been retroactively restated to reflect the reverse stock split resulting in the transfer of $119 from common stock to additional paid in capital at January 1, 2020. |
Stock-Based Compensation |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-Based Compensation | Note 8. Stock-Based Compensation
Restricted Stock Awards
On May 20, 2017, the Company established the Virpax Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (the “Plan”). The Company’s Board of Directors (the “Board”), acting through its Equity Incentive Plan Committee, has determined that it would be to the advantage and best interest of the Company and its stockholders to grant restricted stock awards to certain individuals as compensation to serve as an employee of the Company and as an incentive for increased efforts during such service.
There were 10,420 and 5,506 unvested restricted stock awards issued totaling $61,875 and $50,000 based on a fair value of the Company’s common stock on the date of grant, as of September 30, 2021 and December 31, 2020, respectively. During the three months ended September 30, 2021 and 2020, there were no restricted stock awards granted and 640 and 0 of restricted stock awards were forfeited, respectively. The Company recognized $22,013 and $0 of stock based compensation for vested restricted shares during the three months ended September 30, 2021 and 2020, respectively.
During the nine months ended September 30, 2021 and 2020, there were 15,000 and 6,952 restricted stock awards granted, respectively, and 640 and 20,225 of restricted stock awards were forfeited, respectively. The Company recognized $57,425 and $156,250 of stock based compensation for vested restricted shares during the nine months ended September 30, 2021 and 2020, respectively.
Stock Options
The Plan provides a means for eligible employees, officers, non-employee directors and other individual service providers (collectively, “eligible persons”) to develop a sense of proprietorship and personal involvement in the development and financial success of the Company and to encourage them to devote their best efforts to the business of the Company, thereby advancing the interests of the Company and its stockholders. The Company, by means of the Plan, seeks to retain the services of such eligible persons and to provide incentives for such eligible persons to exert maximum efforts for the success of the Company. The Plan commenced on May 20, 2017 (the “Effective Date”) and is administered by the Compensation Committee of the Board (the “Compensation Committee”); provided that the entire Board may act in lieu of the Compensation Committee on any matter. The maximum aggregate number of shares of common stock which may be issued under all awards granted to participants under the Plan initially shall be 303,382 shares. The number of authorized shares available for issuance under the Plan shall automatically increase on January 1st of each year commencing on January 1 following the Effective Date and on each January 1 thereafter until the expiration date, in an amount equal to six percent (6%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Plan shall remain in effect, subject to the right of the Board to amend or terminate the Plan at any time until the earlier of the tenth (10th) anniversary of the Effective Date. In the event of a termination of continuous service (other than as a result of a change of control, as defined in the Plan), unvested stock options generally shall terminate and, with regard to vested stock options, the exercise period shall be the lesser of the original expiration date or three months from the date continuous service terminates.
On April 25, 2020, the Company amended and restated the Plan to grant stock options to non-employee directors. Stock options to purchase 20,225 shares of common stock shall automatically be granted under the Plan to each non-employee director who is first appointed or elected to the Board. In addition, on January 1 of each year, each then serving non-employee director of the Company shall automatically be granted under the Plan (i) that number of options having a value of $25,000 calculated on the grant date in accordance with the Black-Scholes option pricing model and shall be exercisable as to 100% of the number of shares of common stock covered thereby on the twelve-month anniversary of the grant date, and shall have an exercise price equal to 100% of the Fair Market Value (as defined in the Plan) of a share of Common Stock on the date of grant. Also, on January 1 of each year, each then serving member of the Science and Technology Committee of the Board (the “Science and Technology Committee”) shall automatically be granted stock options to purchase 2,022 shares of Common Stock under the Plan, and the Chair of the Science and Technology Committee shall be granted stock options to purchase an additional 3,033 shares of Common Stock under the Plan. These options have the same terms and conditions as the options granted to the non-employee directors noted above. Options due to directors for the year beginning January 1, 2021 pursuant to the Plan were granted on April 7, 2021.
Stock-based compensation expense for the three months ended September 30, 2021 and 2020 was $141,773 and $435,415, respectively. The Company recorded $121,585 and $435,415 of this stock-based compensation within general and administrative expense and $20,189 and $0 within research and development expense on the accompanying statement of operations for the three months ended September 30, 2021 and 2020, respectively.
Stock-based compensation expense for the nine months ended September 30, 2021 and 2020 was $833,034 and $1,138,096, respectively. The Company recorded $794,462 and $1,138,096 of this stock-based compensation within general and administrative expense and $38,622 and $0 within research and development expense on the accompanying statement of operations for the nine months ended September 30, 2021 and 2020, respectively.
The fair value of option awards is estimated using the Black-Scholes option-pricing model. Exercise price of each award is generally not less than the per share fair value in effect as of that award date. The determination of fair value using the Black-Scholes model is affected by the Company’s share fair value as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest rate and projected employee share option exercise behaviors. Options granted or modified under the Plan during the nine months ended September 30, 2021 and 2020 were valued using the Black-Scholes option-pricing model with the following weighted-average assumptions:
The Company estimates its expected volatility by using a combination of historical share price volatilities of similar companies within our industry. The risk-free interest rate assumption is based on observed interest rates for the appropriate term of the Company’s options on a grant date. The expected option term assumption is estimated using the simplified method and is based on the mid-point between vest date and the remaining contractual term of the option, since the Company does not have sufficient exercise history to estimate expected term of its historical option awards.
The following is a summary of stock option activity under the stock option plan for the nine months ended September 30, 2021 and for the year ended December 31, 2020:
The weighted-average grant-date fair value of stock options granted during the nine months ended September 30, 2021 and year ended December 31, 2020 was $3.06 and $5.66, respectively.
As of September 30, 2021, there was $600,810 of total time-based unrecognized compensation costs related to unvested stock options stock. These costs are expected to be recognized over a weighted average period of 2.01 years. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related-Party Transactions |
9 Months Ended |
|---|---|
Sep. 30, 2021 | |
| Related Party Transactions [Abstract] | |
| Related-Party Transactions | Note 9. Related-Party Transactions
As discussed in Note 5, in October 2018 and January 2019 the Company issued notes with an aggregate principal amount of $1,000,000. These notes were issued to Anthony Mack, Chief Executive Officer and significant investor of the Company and were repaid with the net proceeds from the Company’s Underwritten Public Offering. In addition, in January 2021, the Company issued notes with an aggregate principal amount of $75,000 and $25,000, respectively. These notes were issued to Anthony Mack, Chief Executive Officer and significant investor of the Company for $75,000 and Christopher Chipman, Chief Financial Officer, for $25,000, and were paid off with the proceeds from the Company’s initial public offering.
As discussed in Note 6, the Company’s Chief Executive Officer elected to temporarily defer his salary. Deferred compensation due to the Company’s Chief Executive Officer amounted to $0 and $1,005,000 as of September 30, 2021 and December 31, 2020, respectively, which was repaid with the net proceeds from the Company’s secondary offering. In March 2021, the Company’s Chief Executive Officer ceased deferring compensation. |
Research and Development and License Agreements |
9 Months Ended |
|---|---|
Sep. 30, 2021 | |
| Research and Development [Abstract] | |
| Research and Development and License Agreements | Note 10. Research and Development and License Agreements
MedPharm Limited
Research and Option Agreement
On April 11, 2017, the Company entered into a research and option agreement, as amended on May 30, 2018 (the “MedPharm Research and Option Agreement”), with MedPharm Limited, a company organized and existing under the laws of the United Kingdom (“MedPharm”), pursuant to which MedPharm granted the Company an option to obtain an exclusive, world-wide, royalty bearing license to use certain technology developed by MedPharm. Pursuant to the agreement, MedPharm will conduct certain research and development of proprietary formulations incorporating certain MedPharm technologies and certain of the Company’s proprietary molecules.
Under the MedPharm Research and Option Agreement, MedPharm granted the Company an option (the “MedPharm Option”) to obtain an exclusive (even to MedPharm), worldwide, sub-licensable (through multiple tiers), royalty bearing, irrevocable license to research, develop, market, commercialize, and sell any product utilizing MedPharm’s spray formulation technology which is the result of the activities performed under the MedPharm Research and Option Agreement, subject to the Company’s entry into a definitive license agreement with MedPharm. In order to exercise the MedPharm Option, the Company must provide MedPharm with written notice of such exercise before the end of the Option Period (as defined in the MedPharm Research and Option Agreement). The Option Period is subject to extension upon mutual agreement with MedPharm.
Pursuant to the MedPharm Research and Option Agreement, the Company has a right of first refusal with respect to any license or commercial arrangement involving any Licensed Intellectual Property (as defined in the MedPharm Research and Option Agreement) in combination with any Virpax Molecule (as defined in the MedPharm Research and Option Agreement). In the event that MedPharm reaches an agreement with respect to a license or other commercial arrangement that involves technology or molecules covered by the right of first refusal, the Company has ten business days from the date of notice to notify MedPharm of its intention to exercise the right of first refusal and the Company’s intention to match the financial terms of the other license or commercial arrangement.
License Agreement
On June 6, 2017, as a result of the Company’s exercise of the MedPharm Option under the MedPharm Research and Option Agreement, the Company entered into a license agreement, as amended on September 2, 2017 and October 31, 2017 (the “MedPharm License Agreement”), with MedPharm for the exclusive global rights to discover, develop, make, sell, market, and otherwise commercialize any pharmaceutical composition or preparation (in any and all dosage forms) in final form containing one or more compounds, including Diclofenac Epolamine (“Epoladerm”), that was developed, manufactured or commercialized utilizing MedPharm’s spray formulation technology (“MedPharm Product”), to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses). Under the MedPharm License Agreement, the Company is required to make future milestone and royalty payments to MedPharm. We are obligated to make aggregate milestone payments to MedPharm of up to GBP 1.150 million upon the achievement of specified development milestones (payable in Great British Pounds). Additional milestone payments are due upon the achievement of certain development and commercial milestones achieved outside the United States, payable on a country by country basis. Royalty payments must be paid to MedPharm in an amount equal to a single-digit percentage of net sales of all MedPharm Product sold by us during the royalty term in the territory. Royalties shall be payable, on a country-by-country basis, during the period of time commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on December 4, 2028. Each party has the right to terminate the agreement in its entirety upon written notice to the other party if such other party is in material breach of the agreement and has not cured such breach within ninety (90) days after notice from the terminating party indicating the nature of such breach.
LipoCureRx, Ltd.
On March 19, 2018, the Company entered into a license and sublicense agreement (the “LipoCure Agreement”) with LipoCureRx, Ltd., a company organized and existing under the laws of Israel (“LipoCure”), for the sole and exclusive global license and sub-license rights to discover, develop, make, sell, market, and otherwise commercialize bupivacaine liposome, in injectable gel or suspension (“Licensed Compound”) or any pharmaceutical composition or preparation (in any and all dosage forms) in final form, including any combination product, containing a Licensed Compound (“Licensed Product”), including Probudur. Under the LipoCure Agreement, the Company was required to pay an upfront fee upon signing of $150,000 and is required to make future milestone and royalty payments to LipoCure. The Company is obligated to make aggregate milestone payments of up to $19.8 million upon the achievement of specified development and commercial milestones. Royalty payments must be paid in an amount equal to a single digit to low double-digit percentage of annual net sales of royalty qualifying products, subject to certain adjustments. Royalties shall be payable during the period of time, on a country-by-country basis, commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on July 24, 2030. Each party has the right to terminate the agreement in its entirety upon written notice to the other party if such other party is in material breach of the agreement and has not cured such breach within ninety (90) days after notice from the terminating party indicating the nature of such breach.
Nanomerics Ltd.
Nanomerics Collaboration Agreement
On April 11, 2019, the Company entered into an exclusive collaboration and license agreement, as amended (the “Nanomerics Collaboration Agreement”), with Nanomerics Ltd., a company organized and existing under the laws of United Kingdom (“Nanomerics”), for the exclusive world-wide license to develop and commercialize products, including NES100, which contain hydrophilic neuropeptide Leucin5-Enkephalin and an amphiphile compound which is quaternary ammonium palmitoyl glycol chitosan, to engage in a collaborative program utilizing Nanomerics’ knowledge, skills and expertise in the clinical development of products and to attract external funding for such development. The Nanomerics Collaboration Agreement was also amended to include a program for the pre-clinical development of a product for post-traumatic stress disorder.
Under the Nanomerics Collaboration Agreement, the Company is required to make royalty payments equal to a single digit percentage of annual net sales of royalty qualifying products. The Company is also required to make aggregate milestone payments of up to $103 million upon the achievement of specified development and commercial milestones, and sublicense fees for any sublicense relationships we enter into subsequent to the Nanomerics Collaboration Agreement. The Company’s obligation to pay royalties, on a country-by-country basis, shall commence on the date of first commercial sale of its licensed products and shall expire with respect to each separate licensed product, on the latest to occur of (a) the tenth (10th) anniversary of the first commercial sale of the first licensed product; (b) the expiration date of the last to expire of any valid claim (patent is set to expire on November 3, 2034); and, (c) the date upon which a generic product has been on the market for a period of no fewer than ninety (90) days. The Company has the right to terminate the agreement upon 180 days’ prior written notice to Nanomerics. Upon termination, the Company shall assign to Nanomerics all its right title and interest in all results other than results specific to (a) the Device (as defined in the Nanomerics Collaboration Agreement), including its manufacture or use; and (b) the Technology, but excluding any clinical Results relating to the Compound or Licensed Products (all terms as defined in the Nanomerics Collaboration Agreement).
Nanomerics License Agreement (AnQlar)
On August 7, 2020, the Company entered into a collaboration and license agreement with Nanomerics (the “Nanomerics License Agreement”) for the exclusive North American license to develop and commercialize a High-Density Molecular Masking Spray (“AnQlar”) as an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans. Under the Nanomerics License Agreement, the Company is required to make royalty payments within a range of 5% to 15% of annual net sales of royalty qualifying products. The Company’s obligation to pay royalties, on a country-by-country basis, shall commence on the date of first commercial sale of its licensed products and shall expire with respect to each separate licensed product, on the latest to occur of (a) the tenth (10th) anniversary of the first commercial sale of the first licensed product; (b) the expiration date of the last to expire of any valid claim; and, (c) the date upon which a generic product has been on the market for a period of no fewer than ninety (90) days. The Company is also required to make aggregate milestone payments of up to $50 million upon the achievement of specified development and commercial milestones, and sublicense fees for any sublicense relationships the Company enters into subsequent to the Nanomerics License Agreement (any patent that issues from the currently filed provisional patent application would expire on August 24, 2041). The Company has the right to terminate the Nanomerics License Agreement upon sixty (60) days’ prior written notice to Nanomerics. Upon termination, the Company shall assign to Nanomerics all its rights, title and interest in all of its results. Nanomerics has the right to terminate the agreement upon sixty (60) days’ prior written notice if the Company has not secured funding by the Funding Expiry Date (as defined in the Nanomerics License Agreement). On December 31, 2020, the Company amended the Nanomerics License Agreement to extend the Funding Expiry Date to March 31, 2021. Upon the closing of the Company’s IPO, the Funding Expiry Date provision was satisfied on February 19, 2021.
Nanomerics License Agreement (VRP324)
On September 17, 2021, the Company entered into a collaboration and license agreement with Nanomerics (the “Nanomerics License Agreement - VRP324”) for the exclusive worldwide license to develop and commercialize an investigational formulation delivered via the nasal route to enhance pharmaceutical-grade cannabidiol (“CBD”) transport to the brain to potentially treat seizures associated with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome and Dravet syndrome in patients one year of age and older. Lennox-Gastaut syndrome and Dravet syndrome are rare central nervous system diseases considered serious epileptic encephalopathies that cause different types of epileptic seizures as well as cognitive and behavioral changes and are generally resistant to treatment. Under the Nanomerics License Agreement – VRP324, the Company is required to make royalty payments within a range of 5% to 15% of annual net sales of royalty qualifying products. The Company’s obligation to pay royalties, on a country-by-country basis, shall commence on the date of first commercial sale of its licensed products and shall expire with respect to each separate licensed product, on the latest to occur of (a) the tenth (15th) anniversary of the first commercial sale of the first licensed product; (b) the expiration date of the last to expire of any valid claim; and, (c) the date upon which a generic product has been on the market for a period of no fewer than ninety (90) days. The Company paid an upfront milestone payment upon signing of $200,000 and is required to make future milestone and royalty payments of up to $41 million upon the achievement of specified development and commercial milestones, and sublicense fees for any sublicense relationships the Company enters into subsequent to the Nanomerics License Agreement (any patent that issues from the currently filed provisional patent application would expire on August 24, 2041). The Company has the right to terminate the Nanomerics License Agreement upon one hundred and eighty (180) days’ prior written notice to Nanomerics. Upon termination, the Company shall assign to Nanomerics all its rights, title and interest in all of its results. Nanomerics has the right to terminate the agreement upon thirty (30) days’ prior written notice if the Company concludes in writing to Nanomerics that the study aim has not been achieved or the Company notifies Nanomerics that it has decided against proceeding with a Phase III Clinical trial.
Research Agreements
Yissum
On May 12, 2019, the Company entered into an Agreement for Rendering of Research Services (the “May 2019 Yissum Research Agreement”), with Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (“Yissum”). Under the May 2019 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation, preparation and characterization of Liposomal Bupivacaine for size zeta potential, drug loading and rate of drug release. In consideration for the research services, the Company agreed to pay research service fees of $81,000 in equal monthly installments. The Company retains ownership in all its intellectual property rights and any intellectual property belonging to either the Company or Yissum prior to the execution of the May 2019 Yissum Research Agreement will remain the sole property of either the Company or Yissum, respectively. All data generated from the provision of the May 2019 Yissum Research Agreement, including any reports, which are specifically required and contemplated under the May 2019 Yissum Research Agreement, shall be owned by the Company upon full payment of the research services fees. Each party will be entitled to terminate the agreement in the event of a breach by the other party of its obligations under the agreement, including, but not limited to, any payment failure, which is not remedied by the breaching party within thirty (30) days of receipt of written notice from the non-breaching party. All services to be provided under the May 2019 Yissum Research Agreement were completed by March 31, 2020.
On October 11, 2020, the Company entered into an Agreement for Rendering of Research Services with Yissum (the “October 2020 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above under the May 2019 Yissum Research Agreement. Under the October 2020 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation of Liposomal Bupivacaine as well as efficacy and PK studies in animals. In consideration for the research services, the Company agreed to pay research service fees of $81,000 in six equal monthly installments. In connection with the completion of the Company’s IPO, the Company paid Yissum $40,500 towards the total consideration of $81,000. All services to be provided under the October 2020 Yissum Research Agreement were completed by June 30, 2021.
On June 30, 2021, the Company entered into an Agreement for Rendering of Research Services with Yissum (the “June 2021 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above under the October 2020 Yissum Research Agreement. Under the June 2021 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the optimization of the Liposomal Bupivacaine formulation and to increase stability for manufacturing purposes. The Company may terminate the agreement at any time and shall be only responsible to pay Yissum for work performed through the date of termination. In consideration for the research services, the Company agreed to pay research service fees of $337,500 in six equal quarterly installments. All services to be provided under the June 2021 Yissum Research Agreement initiated on July 1, 2021 and are anticipated to be completed towards the end 2022.
Lipocure
On June 29, 2021, the Company entered into an Agreement for Rendering of Research Services (the “June 2021 Lipocure Research Agreement”) with Lipocure RX, Ltd. (“Lipocure”). Under the June 2021 Lipocure Research Agreement, the Company shall provide funding for research and development related to the optimization of the Liposomal Bupivacaine formulation and eventual manufacture of pre-clinical batches including batches for stability testing, animal studies and toxicology work. This will also include work associated with the potential filing of additional provisional patent applications. The Company may terminate the agreement at any time upon 30 days written notice and shall be only responsible to pay Lipocure for work performed through the date of such notice. In consideration for the research services, the Company agreed to pay research service fees of $200,000 upon execution as prepayment for research services as well as $400,000 on July, 1 2021, and five quarterly payments of $270,000 initiating on September 1 2021. The Company also agreed to pay $250,000 to Lipocure upon successful completion of a Chemistry, Manufacturing and Controls “CMC” filing with the U.S. Food and Drug Administration (the (“FDA”). All services to be provided under the June 2021 Lipocure Research Agreement initiated on July 1, 2021 and are anticipated to be completed towards the end 2022. The Company recorded $600,000 in research and development expense for the three and nine months ended September 30, 2021 and $270,000 as a prepaid expense as of September 30, 2021 associated with this agreement.
NCATS-NIH Cooperative Research and Development Agreement
On August 25, 2020, the Company entered into a Cooperative Research and Development Agreement (“CRADA”) with the National Center for Advancing Translational Science (“NCATS”). This collaboration is for the continued development of the Company’s product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. The term of the CRADA is for a period of four years from May 6, 2020 (the effective date of the agreement) and can be terminated by both parties at any time by mutual written consent. In addition, either party may unilaterally terminate the CRADA at any time by providing written notice of at least sixty (60) days before the desired termination date. The agreement provides for studies that are focused on the pre-clinical characterization of NES100 as a novel analgesic for acute and chronic non-cancer pain, and for studies to further develop NES100 through investigative new drug (“IND”) enabling studies. There are certain development “Go/No Go” provisions within the agreement whereby, if certain events occur, or do not occur, NCATS may terminate the CRADA. These “No GO” provisions include: i) lack of efficacy in all animal pain models, ii) no reliable and sensitive bioanalytical method can be developed, iii) manufacturing failure due to inherent process scalability issues, iv) unacceptable toxicity or safety profile to enable clinical dosing, and v) inability to manufacture the NES100 dosage form.
With respect to NCATS rights to any invention made solely by an NCATS employee(s) or made jointly by an NCATS employee(s) and our employee(s), the CRADA grants to the Company an exclusive option to elect an exclusive or nonexclusive commercialization license. For inventions owned solely by NCATS or jointly by NCATS and the Company, and licensed pursuant to the Company’s option, the Company must grant to NCATS a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention practiced throughout the world by or on behalf of the United States government. For inventions made solely by an employee of the Company, we grant to the United States government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention practiced throughout the world by or on behalf of the United States government for research or other government purposes. |
Subsequent Events |
9 Months Ended |
|---|---|
Sep. 30, 2021 | |
| Subsequent Events [Abstract] | |
| Subsequent Events | Note 11. Subsequent Events
The Company has evaluated subsequent events from the balance sheet date through November 15, 2021. The following are material subsequent events: |
Accounting Policies, by Policy (Policies) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basis of Presentation | Basis of Presentation — The interim condensed financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation of the financial position of Virpax at September 30, 2021, and its results of operations and its cash flows for the three and nine months ended September 30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the years ended December 31, 2020 and 2019 and notes thereto. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations of the Securities and Exchange Commission (“SEC”) relating to interim financial statements. The December 31, 2020 balance sheet information was derived from the audited financial statements as of that date.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Use of Estimates | Use of Estimates — The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.
Significant items subject to such estimates and assumptions include research and development accruals and the valuation of stock-based compensation. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basic and Diluted Loss per Share | Basic and Diluted Loss per Share — Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an antidilutive effect. Equivalent common shares excluded from the calculation of diluted net loss per share since their effect is antidilutive due to the net loss of the Company consisted of the following:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash | Cash — At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. Total cash was $41,713,435 and $54,796 as of September 30, 2021 and December 31, 2020, respectively.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value of Financial Instruments | Fair Value of Financial Instruments — The carrying amounts of the Company’s financial instruments, including cash and accounts payable approximate fair value due to the short-term nature of those instruments.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Research and Development | Research and Development — Research and development costs are expensed as incurred. These expenses include the costs of proprietary efforts, as well as costs incurred in connection with certain licensing arrangements and external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based Compensation | Stock-based Compensation — Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. The Company’s policy permits the valuation of stock-based awards granted to non-employees to be measured at fair value at the grant date rather than on an accelerated attribution basis over the vesting period.
Determining the appropriate fair value of share-based awards requires the use of subjective assumptions, including the fair value of the Company’s common shares, and for options, the expected life of the option and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represents management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.
The expected life of options was estimated using the simplified method, as the Company has historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes | Income Taxes — The Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods.
The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of September 30, 2021, the Company had no uncertain income tax positions. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of antidilutive due to the net loss |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prepaid Expenses and Other Current Assets (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prepaid Expenses and Other Current Assets [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of prepaid expenses and other current assets |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Payable and Accrued Liabilities (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Payables and Accruals [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of accounts payable and accrued liabilities |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of notes payables |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-Based Compensation (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Black-Scholes option-pricing model |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of stock option activity |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business and Liquidity (Details) - USD ($) |
1 Months Ended | 9 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|
Sep. 16, 2021 |
Sep. 30, 2021 |
Sep. 30, 2020 |
Dec. 31, 2020 |
Feb. 16, 2020 |
||||
| Business and Liquidity [Line Items] | ||||||||
| Incurred a net loss | $ 7,938,434 | $ 3,634,442 | ||||||
| Accumulated deficit | $ (18,586,278) | $ (10,647,844) | [1] | |||||
| Share issued (in Shares) | 6,670,000 | |||||||
| Initial offering price (in Dollars per share) | $ 6 | $ 10 | ||||||
| Gross proceeds | $ 40,000,000 | |||||||
| Underwriters warrants to purchase shares (in Shares) | 90,000 | |||||||
| Exercise price per share (in Dollars per share) | $ 12.5 | |||||||
| Percentage of initial public offering price | 125.00% | |||||||
| Net proceeds | $ 37,000,000 | |||||||
| IPO [Member] | ||||||||
| Business and Liquidity [Line Items] | ||||||||
| Share issued (in Shares) | 1,800,000 | |||||||
| Gross proceeds | $ 18,000,000 | |||||||
| Net proceeds | $ 15,800,000 | |||||||
| ||||||||
Summary of Significant Accounting Policies (Details) - USD ($) |
9 Months Ended | |
|---|---|---|
Sep. 30, 2021 |
Dec. 31, 2020 |
|
| Accounting Policies [Abstract] | ||
| Total cash | $ 41,713,435 | $ 54,796 |
| Tax benefit | 50.00% |
Summary of Significant Accounting Policies (Details) - Schedule of antidilutive due to the net loss - shares |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2021 |
Sep. 30, 2020 |
Sep. 30, 2021 |
Sep. 30, 2020 |
|
| Stock options [Member] | ||||
| Equivalent common shares | ||||
| Equivalent common shares | 669,067 | 486,101 | 669,067 | 486,101 |
| Warrants [Member] | ||||
| Equivalent common shares | ||||
| Equivalent common shares | 18,436 | 5,056 | 18,436 | 5,056 |
| RRD note conversion [Member] | ||||
| Equivalent common shares | ||||
| Equivalent common shares | 49,897 | 49,897 | ||
Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($) |
9 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Sep. 30, 2021 |
Dec. 31, 2020 |
||||
| Schedule of prepaid expenses and other current assets [Abstract] | |||||
| Prepaid insurance | $ 421,742 | $ 8,257 | |||
| Prepaid research and development | 1,092,890 | ||||
| Legal retainer | 3,050 | 3,643 | |||
| Consulting fees | 34,250 | 5,838 | |||
| Other prepaid expenses and current assets | 7,666 | 534 | |||
| Total prepaid expenses and other current assets | $ 1,559,598 | $ 18,273 | [1] | ||
| |||||
Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities - USD ($) |
Sep. 30, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Schedule of accounts payable and accrued liabilities [Abstract] | ||
| Accrued payroll and deferred CEO compensation | $ 69,898 | $ 1,031,923 |
| Research and development expenses | 634,627 | 1,045,503 |
| Insurance premiums | 211,981 | 2,874 |
| Legal expenses | 872,795 | 437,471 |
| Professional fees | 9,882 | 253,462 |
| Interest payable/accrued | 270,000 | |
| Accounting consulting fees | 2,054 | 45,904 |
| Tax expenses | 10,000 | 13,365 |
| Other | 571 | 15,422 |
| Total accounts payable and accrued liabilities | $ 1,811,808 | $ 3,115,924 |
Notes Payable (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2021 |
Feb. 28, 2021 |
Jan. 31, 2021 |
Sep. 30, 2021 |
Sep. 30, 2020 |
Sep. 30, 2021 |
Sep. 30, 2020 |
Dec. 31, 2020 |
May 04, 2020 |
Aug. 29, 2019 |
Jan. 15, 2019 |
Oct. 01, 2018 |
|
| Notes Payable (Details) [Line Items] | ||||||||||||
| Promissory note | $ 72,100 | |||||||||||
| Interest rate | 1.00% | |||||||||||
| Accrued interest | $ 34,544 | |||||||||||
| Notes payable description | the Company issued notes with an aggregate principal amount of $75,000 and $25,000, respectively. These notes were issued to Anthony Mack for $75,000 and Christopher Chipman, Chief Financial Officer, for $25,000. These notes bore interest as a rate of 1.35% per annum and were subsequently fully repaid with proceeds from the IPO, including accrued interest of $122 and $41, respectively. | |||||||||||
| Forgiveness amount | $ 61,816 | |||||||||||
| Repayments of debt | $ 10,284 | |||||||||||
| Interest expense | $ 28,892 | $ 45,709 | $ 93,640 | $ 129,600 | ||||||||
| Promissory Note 2018 [Member] | ||||||||||||
| Notes Payable (Details) [Line Items] | ||||||||||||
| Promissory note | $ 500,000 | |||||||||||
| Interest rate | 11.19% | |||||||||||
| Promissory note | 500,000 | 500,000 | ||||||||||
| Accrued interest | 166,296 | |||||||||||
| Promissory Note 2019 [Member] | ||||||||||||
| Notes Payable (Details) [Line Items] | ||||||||||||
| Promissory note | $ 500,000 | 500,000 | $ 500,000 | |||||||||
| Interest rate | 11.19% | |||||||||||
| Accrued interest | $ 149,977 | |||||||||||
| RRD International, LLC [Member] | ||||||||||||
| Notes Payable (Details) [Line Items] | ||||||||||||
| Promissory note | $ 493,480 | $ 400,000 | ||||||||||
| Accrued interest | 34,544 | |||||||||||
| Fixed rate | 10.00% | |||||||||||
| Balance amount on note | $ 528,024 | |||||||||||
| RRD International, LLC [Member] | Maximum [Member] | ||||||||||||
| Notes Payable (Details) [Line Items] | ||||||||||||
| Increased the amount of principal | $ 600,000 | |||||||||||
Notes Payable (Details) - Schedule of notes payables |
9 Months Ended |
|---|---|
|
Sep. 30, 2021
USD ($)
| |
| Related party notes payable | |
| Related party notes payable, Ending Balance | $ 1,100,000 |
| Total related party notes payable, Beginning Balance | 1,000,000 |
| Total related party notes payable, Debt Forgiveness | |
| Total related party notes payable, Notes Issued | 100,000 |
| Total related party notes payable, Note Payments | (1,100,000) |
| Total related party notes payable, Ending Balance | |
| Less: Current portion of notes payable, Beginning Balance | 543,990 |
| Less: Current portion of notes payable, Debt Forgiveness | (61,816) |
| Less: Current portion of notes payable, Notes Issued | 100,000 |
| Less: Current portion of notes payable, Note Payments | (582,174) |
| Less: Current portion of notes payable, Ending Balance | |
| Total non-current portion of notes payable, Beginning Balance | 1,021,590 |
| Total non-current portion of notes payable, Debt Forgiveness | |
| Total non-current portion of notes payable, Notes Issued | |
| Total non-current portion of notes payable, Note Payments | (1,021,590) |
| Total non-current portion of notes payable, Ending Balance | |
| Anthony Mack 2018 Promissory Note [Member] | |
| Related party notes payable | |
| Related party notes payable, Beginning Balance | 500,000 |
| Related party notes payable, Debt Forgiveness | |
| Related party notes payable, Notes Issued | |
| Related party notes payable, Note Payments | (500,000) |
| Related party notes payable, Ending Balance | |
| Total related party notes payable, Note Payments | |
| Anthony Mack 2019 Promissory Note [Member] | |
| Related party notes payable | |
| Related party notes payable, Beginning Balance | 500,000 |
| Related party notes payable, Debt Forgiveness | |
| Related party notes payable, Notes Issued | |
| Related party notes payable, Note Payments | (500,000) |
| Related party notes payable, Ending Balance | |
| Total related party notes payable, Note Payments | |
| Related party notes payable [Member] | |
| Related party notes payable | |
| Related party notes payable, Beginning Balance | |
| Related party notes payable, Debt Forgiveness | |
| Related party notes payable, Notes Issued | 100,000 |
| Related party notes payable, Note Payments | (100,000) |
| Related party notes payable, Ending Balance | |
| Total related party notes payable, Note Payments | |
| RRD Note [Member] | |
| Related party notes payable | |
| Notes payable, Beginning Balance | 493,480 |
| Notes payable, Debt Forgiveness | |
| Notes payable, Notes Issued | |
| Notes payable, Note Payments | (493,480) |
| Notes payable, Ending Balance | |
| Total notes payable, Beginning Balance | 1,565,580 |
| Total notes payable, Debt Forgiveness | (61,816) |
| Total notes payable, Notes Issued | 100,000 |
| Total notes payable, Note Payments | (1,603,764) |
| Total notes payable, Ending Balance | |
| SBA PPP Loan [Member] | |
| Related party notes payable | |
| Notes payable, Beginning Balance | 72,100 |
| Notes payable, Debt Forgiveness | (61,816) |
| Notes payable, Notes Issued | |
| Notes payable, Note Payments | (10,284) |
| Notes payable, Ending Balance |
Commitments and Contingencies (Details) - USD ($) |
Sep. 30, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Chief Executive Officer [Member] | ||
| Commitments and Contingencies [Abstract] | ||
| Deferred compensation | $ 0 | $ 1,005,000 |
Stockholders' Equity (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jan. 02, 2020 |
Sep. 16, 2021 |
Feb. 19, 2021 |
Nov. 19, 2020 |
Sep. 30, 2021 |
Jun. 30, 2021 |
Sep. 30, 2020 |
Jun. 30, 2020 |
Mar. 31, 2020 |
Sep. 30, 2021 |
Sep. 30, 2020 |
Dec. 31, 2020 |
Feb. 16, 2020 |
|
| Stockholder's Equity [Abstract] | |||||||||||||
| Preferred stock shares authorized | 10,000,000 | 10,000,000 | 10,000,000 | ||||||||||
| Preferred stock par value (in Dollars per share) | $ 0.00001 | $ 0.00001 | $ 0.00001 | ||||||||||
| Common stock shares authorized | 100,000,000 | 100,000,000 | 100,000,000 | ||||||||||
| Common stock par value (in Dollars per share) | $ 0.00001 | $ 0.00001 | $ 0.00001 | ||||||||||
| Net proceeds (in Dollars) | $ 18,000,000 | ||||||||||||
| Net proceeds (in Dollars) | $ 36,999,465 | ||||||||||||
| Common stock shares | 10,917 | 139,220 | |||||||||||
| Gross proceeds (in Dollars) | $ 108,000 | $ 1,376,900 | |||||||||||
| Common stock gross proceeds (in Dollars) | $ 40,000,000 | ||||||||||||
| Shares issued | 6,670,000 | ||||||||||||
| Shares issued | 240 | 533 | |||||||||||
| Accounts payable totaling (in Dollars) | $ 2,382 | $ 5,288 | |||||||||||
| Shares of common stock | 90,000 | ||||||||||||
| Exercise price per share (in Dollars per share) | $ 12.5 | ||||||||||||
| Initial public offering price | 125.00% | ||||||||||||
| Number of complex and subjective variables years | 5 years | ||||||||||||
| Price volatility | 100.00% | ||||||||||||
| Risk-free interest rate | 0.60% | ||||||||||||
| Warrants purchase shares | 18,436 | ||||||||||||
| Reverse stock split, description | the Company filed an amendment to its Articles of Incorporation and effected 1-for-4.944260256 reverse stock split of its issued and outstanding shares of common stock, $0.00001 par value, whereby 15,550,627 outstanding shares of the Company’s common stock were exchanged for 3,145,153 newly issued shares of the Company’s common stock. Under the terms of the reverse stock split, fractional shares issuable to stockholders were rounded to the nearest whole share, with cash paid in lieu of any fractional shares, resulting in a reverse split of 1-for-4.944260256. | ||||||||||||
| Warrants outstanding | 944,260,256 | ||||||||||||
| Transfer amount (in Dollars) | $ 119 | ||||||||||||
| Preferred Stock [Member] | |||||||||||||
| Stockholder's Equity [Abstract] | |||||||||||||
| Preferred stock shares authorized | 10,000,000 | 10,000,000 | |||||||||||
| Preferred stock par value (in Dollars per share) | $ 0.00001 | $ 0.00001 | |||||||||||
| Common Stock [Member] | |||||||||||||
| Stockholder's Equity [Abstract] | |||||||||||||
| Common stock shares authorized | 100,000,000 | 100,000,000 | |||||||||||
| Common stock par value (in Dollars per share) | $ 0.00001 | $ 0.00001 | |||||||||||
| Share issued | (15,000) | (3,160) | (3,792) | ||||||||||
| Shares issued | 45,448 | 45,448 | |||||||||||
| Exercise of option | 87,751 | ||||||||||||
| Fair value of warrants issued to underwriters (in Dollars) | $ 639,000 | ||||||||||||
| Warrant [Member] | |||||||||||||
| Stockholder's Equity [Abstract] | |||||||||||||
| Shares issued | 40,221 | 40,221 | |||||||||||
| Exercise of warrants | 76,620 | ||||||||||||
| CEO [Member] | |||||||||||||
| Stockholder's Equity [Abstract] | |||||||||||||
| Shares of common stock | 40,450 | ||||||||||||
| Common stock gross proceeds (in Dollars) | $ 400,000 | ||||||||||||
| Mr. Mack [Member] | |||||||||||||
| Stockholder's Equity [Abstract] | |||||||||||||
| Shares of common stock | 8,999 | ||||||||||||
| Common stock gross proceeds (in Dollars) | $ 89,000 | ||||||||||||
| IPO [Member] | |||||||||||||
| Stockholder's Equity [Abstract] | |||||||||||||
| Shares of common stock | 1,800,000 | ||||||||||||
| Net proceeds (in Dollars) | $ 15,783,207 | ||||||||||||
| Share issued | 6,670,000 | ||||||||||||
| Common stock gross proceeds (in Dollars) | $ 18,000,000 | ||||||||||||
| Shares issued | 1,800,000 | ||||||||||||
Stock-Based Compensation (Details) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Apr. 25, 2020 |
May 20, 2017 |
Sep. 30, 2021 |
Jun. 30, 2021 |
Mar. 31, 2021 |
Sep. 30, 2020 |
Jun. 30, 2020 |
Mar. 31, 2020 |
Sep. 30, 2021 |
Sep. 30, 2020 |
Dec. 31, 2020 |
|
| Stock-Based Compensation (Details) [Line Items] | |||||||||||
| Restricted stock awards, description | There were 10,420 and 5,506 unvested restricted stock awards issued totaling $61,875 and $50,000 based on a fair value of the Company’s common stock on the date of grant, as of September 30, 2021 and December 31, 2020, respectively. During the three months ended September 30, 2021 and 2020, there were no restricted stock awards granted and 640 and 0 of restricted stock awards were forfeited, respectively. The Company recognized $22,013 and $0 of stock based compensation for vested restricted shares during the three months ended September 30, 2021 and 2020, respectively. During the nine months ended September 30, 2021 and 2020, there were 15,000 and 6,952 restricted stock awards granted, respectively, and 640 and 20,225 of restricted stock awards were forfeited, respectively. The Company recognized $57,425 and $156,250 of stock based compensation for vested restricted shares during the nine months ended September 30, 2021 and 2020, respectively. | ||||||||||
| Shares of common stock outstanding, percentage | 6.00% | 6.00% | |||||||||
| Stock options to purchase common shares (in Shares) | 20,225 | ||||||||||
| Stock-based compensation exercisable percentage | 100.00% | ||||||||||
| Fair market value of common stock percentage | 100.00% | ||||||||||
| Additional shares of common stock (in Shares) | 3,033 | ||||||||||
| Stock-based compensation | $ 141,773 | $ 321,427 | $ 369,884 | $ 435,415 | $ 571,691 | $ 130,990 | |||||
| Stock-based compensation within general and administrative expense | 121,585 | 435,415 | $ 794,462 | $ 1,138,096 | |||||||
| Stock-based compensation within research and development expense | 20,189 | $ 0 | 38,622 | 0 | |||||||
| Share based compensation expense | $ 833,034 | $ 1,138,096 | |||||||||
| Weighted-average grant-date fair value of stock options (in Dollars per share) | $ 3.06 | $ 5.66 | |||||||||
| Stock based compensation unrecognized costs | $ 600,810 | $ 600,810 | |||||||||
| Weighted average term | 2 years 3 days | ||||||||||
| Initial Issuance Under Plan [Member] | |||||||||||
| Stock-Based Compensation (Details) [Line Items] | |||||||||||
| Aggregate number of share issued (in Shares) | 303,382 | ||||||||||
| Stock Option [Member] | |||||||||||
| Stock-Based Compensation (Details) [Line Items] | |||||||||||
| Stock options to purchase common shares (in Shares) | 2,022 | ||||||||||
| Black-Scholes Option Pricing Model [Member] | |||||||||||
| Stock-Based Compensation (Details) [Line Items] | |||||||||||
| Number of stock option based value | $ 25,000 | ||||||||||
Stock-Based Compensation (Details) - Schedule of Black-Scholes option-pricing model |
9 Months Ended | |
|---|---|---|
Sep. 30, 2021 |
Sep. 30, 2020 |
|
| Schedule of Black-Scholes option-pricing model [Abstract] | ||
| Expected term (years) | 5 years 9 months | 5 years 2 months 26 days |
| Risk-free interest rate | 1.04% | 0.48% |
| Expected volatility | 79.07% | 68.50% |
| Expected dividend yield | 0.00% | 0.00% |
Stock-Based Compensation (Details) - Schedule of stock option activity - USD ($) |
9 Months Ended | 12 Months Ended |
|---|---|---|
Sep. 30, 2021 |
Dec. 31, 2020 |
|
| Schedule of stock option activity [Abstract] | ||
| Number of Shares, Options outstanding Beginning | 486,101 | 236,458 |
| Weighted- Average Exercise Price, Options outstanding Beginning | $ 9.89 | $ 9.89 |
| Weighted- Average Remaining Contractual Term (Years), Options outstanding Beginning | 8 years 11 months 15 days | |
| Aggregate Intrinsic Value, Options outstanding Beginning | ||
| Number of Shares, Options outstanding Ending | 669,067 | 486,101 |
| Weighted- Average Exercise Price, Options outstanding Ending | $ 7.75 | $ 9.89 |
| Weighted- Average Remaining Contractual Term (Years), Options outstanding Ending | 8 years 7 months 2 days | 8 years 8 months 4 days |
| Aggregate Intrinsic Value, Options outstanding Ending | ||
| Number of Shares, Options exercisable | 415,394 | |
| Weighted- Average Exercise Price, Options exercisable | $ 9.51 | |
| Weighted- Average Remaining Contractual Term (Years), Options exercisable | 8 years 14 days | |
| Aggregate Intrinsic Value, Options exercisable | ||
| Number of Shares, Forfeited | (20,225) | |
| Weighted- Average Exercise Price, Forfeited | $ 9.89 | |
| Number of Shares, Exercised | (87,751) | |
| Weighted- Average Exercise Price, Exercised | $ 9.89 | |
| Number of Shares, Granted | 270,717 | 269,868 |
| Weighted- Average Exercise Price, Granted | $ 4.62 | $ 9.89 |
| Aggregate Intrinsic Value, Granted |
Related-Party Transactions (Details) - USD ($) |
1 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Jan. 31, 2021 |
Jan. 31, 2019 |
Sep. 30, 2021 |
Dec. 31, 2020 |
|
| Related-Party Transactions (Details) [Line Items] | ||||
| Related-party transactions | As discussed in Note 5, in October 2018 and January 2019 the Company issued notes with an aggregate principal amount of $1,000,000. | |||
| Christopher Chipman [Member] | ||||
| Related-Party Transactions (Details) [Line Items] | ||||
| Aggregate principal amount | $ 25,000 | |||
| Chief Executive Officer [Member] | ||||
| Related-Party Transactions (Details) [Line Items] | ||||
| Deferred compensation | 0 | $ 1,005,000 | ||
| Anthony Mack [Member] | ||||
| Related-Party Transactions (Details) [Line Items] | ||||
| Aggregate principal amount | $ 75,000 | $ 75,000 | ||
| Chief Financial Officer [Member] | ||||
| Related-Party Transactions (Details) [Line Items] | ||||
| Aggregate principal amount | $ 25,000 | |||
Research and Development and License Agreements (Details) £ in Thousands |
1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jul. 02, 2021
USD ($)
|
Oct. 11, 2020
USD ($)
|
Aug. 07, 2020
USD ($)
|
May 12, 2019
USD ($)
|
Apr. 11, 2019
USD ($)
|
Jun. 06, 2017
GBP (£)
|
Aug. 25, 2020 |
Mar. 19, 2018 |
Sep. 30, 2021
USD ($)
|
Jun. 30, 2021
USD ($)
|
Sep. 30, 2021
USD ($)
|
Sep. 01, 2021
USD ($)
|
|
| Research and Development and License Agreements (Details) [Line Items] | ||||||||||||
| Description of lipocure agreement | the LipoCure Agreement, the Company was required to pay an upfront fee upon signing of $150,000 and is required to make future milestone and royalty payments to LipoCure. The Company is obligated to make aggregate milestone payments of up to $19.8 million upon the achievement of specified development and commercial milestones. Royalty payments must be paid in an amount equal to a single digit to low double-digit percentage of annual net sales of royalty qualifying products, subject to certain adjustments. Royalties shall be payable during the period of time, on a country-by-country basis, commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on July 24, 2030. | |||||||||||
| Nanomerics collaboration agreement,description | the Company entered into an exclusive collaboration and license agreement, as amended (the “Nanomerics Collaboration Agreement”), with Nanomerics Ltd., a company organized and existing under the laws of United Kingdom (“Nanomerics”), for the exclusive world-wide license to develop and commercialize products, including NES100, which contain hydrophilic neuropeptide Leucin5-Enkephalin and an amphiphile compound which is quaternary ammonium palmitoyl glycol chitosan, to engage in a collaborative program utilizing Nanomerics’ knowledge, skills and expertise in the clinical development of products and to attract external funding for such development. | |||||||||||
| Description of cooperative research and development agreement | The term of the CRADA is for a period of four years from May 6, 2020 (the effective date of the agreement) and can be terminated by both parties at any time by mutual written consent. | |||||||||||
| Minimum [Member] | ||||||||||||
| Research and Development and License Agreements (Details) [Line Items] | ||||||||||||
| Royalty payments | 5.00% | |||||||||||
| Maximum [Member] | ||||||||||||
| Research and Development and License Agreements (Details) [Line Items] | ||||||||||||
| Royalty payments | 15.00% | |||||||||||
| MedPharm License Agreement [Member] | ||||||||||||
| Research and Development and License Agreements (Details) [Line Items] | ||||||||||||
| Milestone and royalty payments | £ | £ 1,150 | |||||||||||
| Nanomerics Collaboration Agreement [Member] | ||||||||||||
| Research and Development and License Agreements (Details) [Line Items] | ||||||||||||
| Milestone and royalty payments | $ 50,000,000 | $ 103,000,000 | ||||||||||
| Milestone payments | $ 200,000 | |||||||||||
| Royalty payments | 41,000,000 | |||||||||||
| Nanomerics Collaboration Agreement [Member] | Minimum [Member] | ||||||||||||
| Research and Development and License Agreements (Details) [Line Items] | ||||||||||||
| Milestone and royalty payments percentage | 5.00% | |||||||||||
| Nanomerics Collaboration Agreement [Member] | Maximum [Member] | ||||||||||||
| Research and Development and License Agreements (Details) [Line Items] | ||||||||||||
| Milestone and royalty payments percentage | 15.00% | |||||||||||
| Yissum Research Agreement [Member] | ||||||||||||
| Research and Development and License Agreements (Details) [Line Items] | ||||||||||||
| Research service fees | $ 81,000 | |||||||||||
| Description of yissum research agreement | the Company entered into an Agreement for Rendering of Research Services with Yissum (the “October 2020 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above under the May 2019 Yissum Research Agreement. Under the October 2020 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation of Liposomal Bupivacaine as well as efficacy and PK studies in animals. In consideration for the research services, the Company agreed to pay research service fees of $81,000 in six equal monthly installments. In connection with the completion of the Company’s IPO, the Company paid Yissum $40,500 towards the total consideration of $81,000. All services to be provided under the October 2020 Yissum Research Agreement were completed by June 30, 2021. | |||||||||||
| Research service fees paid in equal monthly installments | $ 81,000 | |||||||||||
| Research and development expense | $ 81,000 | |||||||||||
| Research and development in process | $ 337,500 | |||||||||||
| Lipocure Research Agreement [Member] | ||||||||||||
| Research and Development and License Agreements (Details) [Line Items] | ||||||||||||
| Research service fees | $ 200,000 | |||||||||||
| Research and development expense | $ 600,000 | 600,000 | ||||||||||
| Research and development in process | 270,000 | |||||||||||
| Research and Development Expense, Software (Excluding Acquired in Process Cost) | $ 400,000 | |||||||||||
| Research service fees paid in quarterly payments | $ 270,000 | |||||||||||
| Research and Development Expenses1 | $ 250,000 | |||||||||||